Document:

Asset Purchase Agreement

 EXHIBIT 10.9 
 ASSET PURCHASE AND SALE AGREEMENT 
 By and Between 
 CHEMTURA CORPORATION 
 and

 AMVAC CHEMICAL CORPORATION 
 Dated December 14, 2007 

 TABLE OF CONTENTS 
  
  

							
	 	  	 	  	 Page

			
	1.	  	DEFINITIONS	  	1
			
	2.	  	SALE AND TRANSFER OF THE PURCHASED ASSETS; LIABILITIES; CLOSING	  	5
				
		  	2.1	  	PURCHASED ASSETS; LIABILITIES	  	5
		  	2.2	  	PURCHASE PRICE; CLOSING INVENTORY	  	7
		  	2.3	  	CLOSING	  	8
			
	3.	  	REPRESENTATIONS AND WARRANTIES OF SELLER	  	9
				
		  	3.1	  	ORGANIZATION; AUTHORITY; NO CONFLICT; CONSENTS	  	9
		  	3.2	  	TITLE	  	10
		  	3.3	  	LITIGATION; COMPLIANCE WITH LEGAL REQUIREMENTS	  	10
		  	3.4	  	BROKERS OR FINDERS	  	10
		  	3.5	  	ABSENCE OF CHANGE	  	10
		  	3.6	  	TRANSFERRED REGISTRATIONS	  	11
		  	3.7	  	TRANSFERRED REGISTRATION DATA	  	11
		  	3.8	  	TRANSFERRED TRADEMARKS	  	11
		  	3.9	  	TRANSFERRED KNOW-HOW	  	12
		  	3.10	  	CLOSING INVENTORY	  	12
		  	3.11	  	CONTRACTS	  	13
		  	3.12	  	FINANCIAL INFORMATION	  	13
			
	4.	  	REPRESENTATIONS AND WARRANTIES OF BUYER	  	13
				
		  	4.1	  	ORGANIZATION; AUTHORITY; NO CONFLICT; CONSENTS	  	13
		  	4.2	  	LITIGATION; COMPLIANCE WITH LEGAL REQUIREMENTS	  	14
		  	4.3	  	BROKERS OR FINDERS	  	14
		  	4.4	  	PAYMENTS OF BUYER	  	15
		  	4.5	  	INSPECTIONS; NO OTHER REPRESENTATIONS	  	15
			
	5.	  	COVENANTS	  	15
				
		  	5.1	  	***	  	15
		  	5.2	  	EXECUTION AND DELIVERY OF OTHER TRANSACTION DOCUMENTS	  	15
		  	5.3	  	ACCESS AND INVESTIGATION	  	16
		  	5.4	  	PRODUCT REGISTRATIONS	  	17
		  	5.5	  	CONFIDENTIALITY	  	18
		  	5.6	  	PUBLICITY	  	18

  

 i 

							
		  	5.7	  	TRANSFER TAXES	  	19
		  	5.8	  	CERTAIN DOCUMENTS	  	19
			
	6.	  	INDEMNIFICATION; REMEDIES	  	20
				
		  	6.1	  	INDEMNIFICATION AND PAYMENT OF DAMAGES BY SELLER	  	20
		  	6.2	  	INDEMNIFICATION AND PAYMENT OF DAMAGES BY BUYER	  	20
		  	6.3	  	SURVIVAL; TIME LIMITATIONS	  	20
		  	6.4	  	LIMITATIONS ON DAMAGES	  	21
		  	6.5	  	PROCEDURE FOR INDEMNIFICATION-THIRD-PARTY CLAIMS	  	21
		  	6.6	  	PROCEDURE FOR INDEMNIFICATION-OTHER CLAIMS	  	22
		  	6.7	  	NET RECOVERY; MITIGATION; ETC.	  	22
			
	7.	  	GENERAL PROVISIONS	  	23
				
		  	7.1	  	EXPENSES	  	23
		  	7.2	  	NOTICES	  	23
		  	7.3	  	DISPUTE RESOLUTION; GOVERNING LAW; JURISDICTION	  	24
		  	7.4	  	NO IMPLIED WAIVERS; NO JURY TRIAL	  	24
		  	7.5	  	ENTIRE AGREEMENT AND MODIFICATION	  	25
		  	7.6	  	ASSIGNMENTS, SUCCESSORS, AND NO THIRD-PARTY RIGHTS	  	25
		  	7.7	  	SEVERABILITY	  	25
		  	7.8	  	SECTION HEADINGS; CONSTRUCTION	  	25
		  	7.9	  	TIME OF THE ESSENCE	  	26
		  	7.10	  	COUNTERPARTS	  	26
			
	EXHIBITS	  	[NOTE: Conform after edit]	  	

 *** 
  

 ii 

 ASSET PURCHASE AND SALE AGREEMENT 
 This Asset Purchase and Sale Agreement (this “Agreement”) is made as of the 15th day of December 2007, by and between Chemtura
Corporation, a Delaware corporation (“Seller”) and AMVAC Chemical Corporation, a California corporation (“Buyer”). 
 RECITALS 
 WHEREAS, Buyer and/or its Affiliates desires to purchase from Seller and/or its
Affiliates, and Seller and/or its Affiliates desires to sell to Buyer and/or its Affiliates, the Purchased Assets, all for the consideration and on the terms set forth in this Agreement. 
 NOW THEREFORE, for and in consideration of the foregoing and the mutual covenants and agreements contained herein, and intending to be legally bound
hereby, Buyer and Seller hereby agree as follows: 
  

	1.	DEFINITIONS 

 For purposes of this Agreement, the following terms
shall have the meanings specified or referred to in this Article 1: 
 “Affiliate” – means, with respect to any Person
(a) any Person directly or indirectly controlling, controlled by or under common control with such Person, (b) any officer, director, general partner, member or trustee of such Person or (c) any Person who is an officer, director,
general partner, member or trustee of any Person described in clauses (a) or (b) of this sentence. For purposes of this definition, the terms “control”, “controlling”, “controlled by” or “under common
control with” shall mean the possession, direct or indirect, of the power to control the management of a Person, whether through the ownership of voting securities, by contract or otherwise. 
 “Agreement” – is defined in the preamble hereof. 
 “Assignment and Assumption Agreement” – means the Assignment and Assumption Agreement in the form attached hereto as Exhibit 1(a) to be entered into by Seller and Buyer at the Closing. 
 “Assumed Liabilities” – is defined in Section 2.1(c) hereof. 
 “Basket” – is defined in Section 6.4(a) hereof. 
 “Bill of Sale”
– means the Bill of Sale in the form attached hereto as Exhibit 1(b) to be entered into by Seller and Buyer at the Closing. 
 “Breach” – a “Breach” of a representation, warranty, covenant, obligation, or other provision of this Agreement will be deemed to have occurred if there is or has been an actual breach of, or any
actual failure to perform or comply with, such representation, warranty, covenant, obligation or other provision. 

 “Buyer” – is defined in the preamble hereof. 
 “Buyer’s Disclosure Schedules” – means the disclosure schedules of Buyer referred to in Article 4 hereof and attached hereto and made a
part hereof. 
 “Buyer Indemnified Persons” – is defined in Section 6.1 hereof. 
 “Closing” – means 6:00 pm EDT on the date hereof. 
 “Closing Inventory” – means Seller’s and its Affiliates’ inventories of the items listed in Exhibit 1(c) attached hereto as of the Closing, including (a) finished goods; (b) raw materials,
packaging and intermediates for use solely for the manufacture, formulation and/or packaging of Products; and (c) semi-finished Products. 
 “Collateral Source” – is defined in Section 6.7 hereof. 
 “Confidential Information”
– is defined in Section 5.5 hereof. 
 “Consent” – means any approval, consent or other authorization.

 “Contemplated Transactions” – means all of the transactions contemplated by this Agreement and the other Transaction
Documents. 
 “CPR” is defined in Section 7.3(b) hereof. 
 “Damages” – is defined in Section 6.1 hereof. 
 “Deferred Purchase
Price” – is defined in Section 2.2(b) hereof. 
 “Encumbrance” – means any lien, pledge, security
interest, right of first refusal, or other like restriction. 
 “Excluded Liabilities” – is defined in Section 2.1(d)
hereof. 
 “Excluded Products” – means the following seed treatment products: (a) System 3 and (b) Prevail.

 “Governmental Body” – means any federal, state, local, municipal, foreign or other governmental body entitled to exercise any
administrative, executive, judicial, legislative, police, regulatory or taxing authority. 
 “Indemnified Person” – means a
Buyer Indemnified Person or a Seller Indemnified Person, as the case may be. 
 “Indemnifying Person” – is defined in
Section 6.5(a) hereof. 
  

 2 

 “Knowledge” – an individual will be deemed to have “Knowledge” of a particular
fact or other matter only if such individual is actually aware of such fact or other matter. 
 “Legal Requirement” – means any
applicable law, statute, treaty, rule, code, ordinance, regulation, order, enforcement action, injunction, judgment, decree or enforceable judicial or administrative interpretation thereof of any Governmental Body. 
 “Liabilities” – means any liabilities, obligations, expenses, claims, taxes or assessments, losses, or damages of or by any Person.

 “Material Adverse Effect” – means a material adverse effect on the Purchased Assets, taken as a whole, except any material
adverse effect (a) related to general economic, regulatory or political conditions or from terrorist acts, declared or undeclared war or other hostilities, (b) that affects the general industry in which the Purchased Assets are owned or
used, (c) relating to changes in accounting requirements, under generally accepted accounting principles or other similar standards, applicable to the Products or (d) relating to the announcement of the Contemplated Transactions.
Notwithstanding anything contained herein to the contrary, no action taken by Seller or Buyer (or any of their Affiliates) expressly required or contemplated by this Agreement or the other Transaction Documents shall be deemed to have a Material
Adverse Effect. 
 “Ordinary Course of Business” – an action taken by a Person will be deemed to have been taken in the
“Ordinary Course of Business” if such action is substantially consistent with the past practices of such Person and is taken in the ordinary course of the normal day-to-day operations of such Person. 
 “PCNB” – means pentachloronitrobenzene 
 “Permitted Encumbrance” – means (a) any Encumbrance for taxes accrued but not yet due or for taxes the validity of which are being contested in good faith by appropriate proceedings or (b) any
statutory carriers’, warehousemen’s, workmen’s or mechanics’ lien or other like Encumbrance that is not yet delinquent or is being contested in good faith by appropriate proceedings. 
 “Person” – means any individual, corporation, general or limited partnership, limited liability company, joint venture, estate,
trust, association, organization, labor union or other entity or Governmental Body. 
 “Proceeding” – means any action,
arbitration, hearing, litigation or suit (whether civil, criminal, administrative, investigative, or informal) commenced, brought, conducted or heard by or before any Governmental Body. 
 “Products” – means the products listed in Exhibit 1(d), but specifically excluding the Excluded Products. 
 “Product Registration” – means a permission, authorization, registration and/or approval from an applicable Governmental Body that is
necessary for the sale of a Product. 
  

 3 

 “Product Registration Data” – means the data, information and studies relating to a
particular active ingredient and its formulations, including its impurities or metabolites, which have been submitted to a Governmental Body in support of an application for a Product Registration. 
 “Purchase Price” – is defined in Section 2.2(a) hereof. 
 “Purchased Assets” – is defined in Section 2.1(a) hereof. 
 “Seller”
– is defined in the preamble hereof. 
 “Seller Indemnified Persons” – is defined in Section 6.2 hereof.

 “Seller’s Disclosure Schedules” – means the disclosure schedules of Seller referred to in Article 3 hereof and attached
hereto and made a part hereof. 
 “Seller’s Knowledge” – means the knowledge of Robert Cannings (with respect to
Sales & Marketing), Alex Dzialo (with respect to Production, Manufacturing & Tolling) and Michael Dupre (with respect to Registrations). 
 “Third-Party Claim” – is defined in Section 6.5(a) hereof. 
 “Threatened” – a
claim, Proceeding, order, dispute, action or other matter will be deemed to have been “Threatened” against a Person if any demand or statement has been made in writing, or any written notice has been given to such Person.

 “Trademark Assignment” – means the Trademark Assignment in the form attached hereto as Exhibit 1(d) to be entered into
by Seller and Buyer at the Closing. 
 “Transaction Documents” – means this Agreement (together with the schedules and exhibits
attached hereto), the Assignment and Assumption Agreement, the Trademark Assignment, the Bill of Sale, and any other documents or agreements executed and/or delivered in connection with the Contemplated Transactions. 
 “Transferred Contracts” – means those contracts to be transferred to Buyer hereunder as identified on Exhibit 1 (e). 
 “Transferred Know-How” – is defined in Section 2.1(a)(iv) hereof. 
 “Transferred Registration Data” – is defined in Section 2.1(a)(ii) hereof. 
 “Transferred Registrations” – is defined in Section 2.1(a)(i) hereof. 
 “Transferred
Trademarks” – is defined Section 2.1(a)(iii) hereof. 
  

 4 

	2.	SALE AND TRANSFER OF THE PURCHASED ASSETS; LIABILITIES; CLOSING 

  

	 	2.1	PURCHASED ASSETS; LIABILITIES. 

 (a)
Purchased Assets. At the Closing, and upon the terms and subject to the conditions of this Agreement, Seller shall, and/or shall cause its applicable Affiliates to, sell and assign to Buyer and/or its designated Affiliates, and Buyer shall,
and/or shall cause its designated Affiliates to, purchase and accept from Seller and/or its applicable Affiliates, all of Seller’s and/or its Affiliates’ right, title and interest existing on the Closing Date in and to the following
assets, free and clear of Encumbrances, other than Permitted Encumbrances (the “Purchased Assets”): 
 (i) Seller’s and/or its Affiliates’ Product Registrations as expressly identified and set forth in Exhibit 2.1(a)(i) (collectively, the “Transferred Registrations”); 
 (ii) Seller’s and/or its Affiliates’ Product Registration Data to the extent specifically relating to and in support of the
Transferred Registrations which, to Seller’s Knowledge, are identified and set forth in Exhibit 2.1(a)(ii) (collectively, the “Transferred Registration Data”) including, without limitation, rights to data compensation
associated therewith; 
 (iii) Seller’s and/or its Affiliates’ trademarks as expressly identified and set forth in
Exhibit 2.1(a)(iii) (collectively, the “Transferred Trademarks”); 
 (iv) Seller’s and/or
its Affiliates’ know-how specifically relating to the formulation of formulated Products, as expressly identified on Exhibit 2.1(a)(v)(collectively, the “Transferred Know-How”) ; 
 (v) Seller and/or its Affiliates’ books, records and files, including without limitation, customer lists, sales and marketing
information, sales records, pricing information, incentive programs, distribution programs, supply information, and all efficacy data to the extent specifically relating to Seller’s and/or its Affiliates’ sales of Products; 
 (vi) Seller’s and/or its Affiliates’ rights under the Transferred Contracts; and 
 (vii) Seller’s and/or its Affiliates’ rights under customer orders for Products received by Seller for which title has not
passed to customer as of the Closing. 
 (b) Excluded Assets. Notwithstanding the foregoing, the Purchased Assets shall
not include any of the following: 
 (i) any cash or accounts receivable (including, but not limited to, any cash or accounts
receivable arising from or relating to the sale of Products by Seller or any of its Affiliates); 
  

 5 

 (ii) any prepaid deposits or prepaid expenses (including, but not limited to, any prepaid
deposits or prepaid expenses arising from or relating to the sale of Products by Seller or any of its Affiliates); 
 (iii)
rights under any contracts or agreements to which Seller is a party relating to the sale of the Products (except to the extent specifically assigned hereunder); 
 (iv) any asset, right or property owned or used by Seller or its Affiliates, or relating to Products, unless such asset, right or property
is expressly identified in Section 2.1(a) as a Purchased Asset; 
 (v) the rights that accrue or will accrue to Seller
under this Agreement or any other Transaction Document; 
 (vi) any Closing Inventory, which is specifically provided for in
Section 2.2(c) hereof; 
 (vii) any inventories of Excluded Products; or 
 (viii)***. 
 (c) Assumed Liabilities. Effective immediately after the Closing, Buyer shall be responsible for and shall assume and agree to pay, discharge or perform, as appropriate, when due the following Liabilities (collectively, the
“Assumed Liabilities”): 
 (i) any Liability arising out of or relating to the Purchased Assets to the
extent that any such Liability is for, relates to or arises during time periods after the Closing; 
 (ii) any Liability
arising out of or relating to the sale of Products or the conduct of the business relating to the Purchased Assets and the sale of Products, to the extent that any such Liability is for or relates to Products sold by Buyer after the Closing
(including, without limitation, any and all storage and warehouse costs associated with the Products incurred on or after the Closing), provided, however, that nothing in this section is intended to relieve Seller of warranty obligations relating to
any Closing Inventory purchased by Buyer from Seller after the Closing; 
 (iii) any tax liability assessed against or with
respect to the Purchased Assets or Products at anytime after the Closing relating to the Purchased Assets or Products sold at any time on or after the Closing; and 
 (iv) any Liability arising out of or relating to any Transferred Contracts to the extent that such Liability is for, relates to or arises
during time periods after the Closing. 
  

 6 

 (d) Excluded Liabilities. Buyer shall not assume or become responsible for the
following Liabilities (collectively, the “Excluded Liabilities”): 
 (i) any Liability arising out of
or relating to the Purchased Assets to the extent that any such Liability is for, relates to and arises during time periods on or prior to the Closing, including, without limitation, those related to the Transferred Contracts; 
 (ii) any Liability arising out of or relating to Seller’s sale of Products to the extent that any such Liability is for, relates to
Products sold by Seller on or prior to the Closing; and 
 (iii) any tax liability assessed against or with respect to the
Purchased Assets or Products at any time on or prior to the Closing relating to the Purchased Assets or Products sold at any time on or prior to the Closing. 
 (iv) any Liability arising out of or relating to rebate or incentive payment programs in effect between Seller and its distributors or
customers. 
 (v) any other liability that is not specifically assumed by Buyer as per Section 2.1 (c) above.

  

	 	2.2	PURCHASE PRICE; CLOSING INVENTORY 

 (a) In
consideration for Seller’s and/or its Affiliates’ sale, assignment and delivery of the Purchased Assets to Buyer and/or its Affiliates, and Seller’s and its Affiliates’ performance of their respective obligations contained in
this Agreement, at the Closing, Buyer shall pay, or cause to be paid, to Seller, by wire transfer to an account designated by Seller, an amount equal to *** )(the “Purchase Price”). 
 (b) In addition, on or before December 15, 2009, Buyer shall pay, or cause to be paid, to Seller, by wire transfer to an account
designated by Seller, an amount, equal to *** less the amount, if any, calculated as per Exhibit 2.2(b) hereto (the “Deferred Purchase Price”). 
 (c) In addition to the foregoing, 
 (i) promptly after the Closing (and following the physical stock taking described in the immediately following paragraph), Seller shall, and/or shall cause its applicable Affiliates to, deliver to Buyer and/or its
applicable Affiliates, the Closing Inventory, which Buyer and/or its Affiliates shall keep as consigned inventory in one or more locations, under Buyer’s control, segregated from Buyer’s other inventory and clearly labeled as the property
of Seller (the “Consigned Storage”). Buyer shall maintain at all times during the term of the consignment provided for herein, all permits required for the storage of the consigned Products and the storage area for such consigned Products
shall comply with all applicable laws and regulations. All storage and unloading costs and all costs of withdrawal of the consgined Products from storage will be for the account of Buyer. Buyer agrees to purchase the Closing Inventory from time to
time on an as needed basis at the prices set forth in Exhibit 2.2(c)(i) (which will be provided to Buyer by Seller immediately after Closing), which prices shall be no greater than Seller’s book value (to be determined with accounting a
valuation principles as consistently applied by Seller maintaining full accounting and valuation consistency with 

  

 7 

 
previous financial statements, in particular providing for sufficient and appropriate depreciation and value adjustments) for such goods; provided that if
Buyer has not purchased all of the Closing Inventory from the Consigned Storage by July 31, 2008, Buyer shall be deemed to have withdrawn any and all Closing Inventory then remaining, as of such date. Title to such Closing Inventory shall
remain with Seller until Buyer withdraws or is deemed to withdraw any such Closing Inventory from Consigned Storage. Risk of loss, however, shall pass to Buyer upon Buyer’s receipt of such Closing Inventory into Consigned Storage. Not later
than the 10th day of each month, Buyer agrees to provide Seller with a written report on a monthly basis indicating the level of Closing Inventory
that has been withdrawn or that is deemed to have been withdrawn from Consigned Inventory during the immediately prior calendar month. Buyer agrees to make payment for Closing Inventory so reported to have been withdrawn or deemed to have been
withdrawn on a net thirty (30) day basis as measured from the date of the applicable monthly report. All purchases of Closing Inventory shall be subject to, and Buyer shall pay, any applicable taxes relating to such purchases, including any
value added taxes. 
 (ii) Seller shall perform a count of the Closing Inventory through either (a) a physical stock
taking of the Closing Inventory which Buyer shall be given the opportunity to observe or (b) written certifications from warehouses holding Closing Inventory. As promptly as possible, but in any event within ten (10) business days after
the Closing Date, Seller shall deliver to Buyer an un-audited statement of the value and quantity of the Closing Inventory based upon the book value as described in the immediately preceding paragraph, as shown in the records of Seller (and/or its
Affiliates) holding such Closing Inventory as of the Closing Date. 
  

	 	2.3	CLOSING 

 The closing of the purchase and sale of the
Purchased Assets (the “Closing”) shall take place on the Closing Date at the offices of Seller located in Middlebury, Connecticut, or at such other place or in such other manner as shall be mutually agreed upon by the
parties. At the Closing, the parties shall take any actions necessary to finalize the transactions contemplated hereunder, including 
 (a) The parties shall execute, and procure where necessary that their Affiliates execute, such deeds or other instruments (including this Agreement) and perform and procure where necessary that their Affiliates perform all other actions as
are necessary to transfer title to and possession of, the Purchased Assets, including, without limitation, the transfer of title to and possession of tangible assets sold pursuant hereto, the assignment of Transferred Registrations, the assignment
of the Transferred Contracts, the transfer of title to and possession of the Transferred Registration Data, the assignment or licensing of Transferred Trademarks and Transferred Know-How, and the transfer of books, records and documentation as
provided hereunder and as are necessary to transfer the rights and obligations provided for in the Assignment and Assumption Agreement; 
 (b) Buyer shall pay the Purchase Price in accordance with Section 2.2 above; and 
  

 8 

 (c) Seller and/or its Affiliates shall execute and deliver the Bill of Sale. 

Each of Seller and Buyer shall cause its respective Affiliates to take any action that is required for the Closing. 
  

	3.	REPRESENTATIONS AND WARRANTIES OF SELLER 

 Except as
set forth in Seller’s Disclosure Schedules, Seller hereby represents and warrants to Buyer as of the date hereof as follows: 
  

	 	3.1	ORGANIZATION; AUTHORITY; NO CONFLICT; CONSENTS 

 (a) Seller is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization. 
 (b) Each of Seller and its Affiliates has the requisite power and authority to (i) sell the Purchased Assets, (ii) execute and deliver the Transaction Documents to which it is a party and
(iii) consummate the Contemplated Transactions required to be consummated by it. Seller has duly executed and delivered this Agreement, and this Agreement constitutes the legal, valid and binding obligation of Seller, enforceable against Seller
in accordance with its terms, subject to applicable bankruptcy, insolvency and other similar laws affecting the enforceability of creditors’ rights generally, general equitable principles, and court discretion in granting equitable remedies.

 (c) Except as set forth in Schedule 3.1(c) of Seller’s Disclosure Schedules, none of Seller’s execution,
delivery nor performance of the Transaction Documents to which it is a party, nor Seller’s consummation of the Contemplated Transactions, will: 
 (i) result in a violation of any of the constituent documents of Seller or any resolution currently in effect adopted by the management organization of Seller; or 
 (ii) result in a violation or breach of, or constitute (with or without due notice or lapse of time or both) a default (or give rise to
any right of termination, cancellation or acceleration) under, any of the terms, conditions or provisions of any note, bond, mortgage, indenture, lease, license, contract, agreement or other instrument or obligation to which Seller is a party or by
which it or any of its properties or assets may be bound, excluding from the foregoing clause (ii) such violations, breaches or defaults which would not, individually or in the aggregate, have a Material Adverse Effect; or 
 (iii) violate any order, writ, injunction, or decree, or, to Seller’s Knowledge, any statute, rule or regulation, applicable to
Seller or any of its properties or assets, excluding from the foregoing clause (iii) such violations, breaches or defaults which would not, individually or in the aggregate, have a Material Adverse Effect; or 
  

 9 

 (iv) to Seller’s Knowledge, give any Governmental Body the right to challenge any of
the Contemplated Transactions. 
 (d) To Seller’s Knowledge, except as set forth in Schedule 3.1(d) of Seller’s
Disclosure Schedules, Seller is not required to give any notice to, or obtain any Consent from any (i) Governmental Body, (ii) Person pursuant to any written contract or (iii) management organization or stockholders of Seller, in
connection with the Contemplated Transactions. 
  

	 	3.2	TITLE 

 (a) Except as set forth in
Schedule 3.2(a) of Seller’s Disclosure Schedules, Seller and its applicable Affiliates are the record and beneficial owners of, and have good and marketable title to, the Purchased Assets, free and clear of Encumbrances, except for the
Permitted Encumbrances. 
 (b) Except as set forth in Schedule 3.2(b) of Seller’s Disclosure Schedules, each of
Seller and its applicable Affiliates has the right, power and authority to sell, assign and deliver the Purchased Assets to Buyer or its Affiliates free and clear of Encumbrances, other than Permitted Encumbrances. 
  

	 	3.3	LITIGATION; COMPLIANCE WITH LEGAL REQUIREMENTS 

 (a) Except as set forth in Schedule 3.3(a) of Seller’s Disclosure Schedules, there are no Proceedings pending or, to Seller’s Knowledge, Threatened, against Seller, (i) involving the Purchased Assets or (ii) that
question the validity of this Agreement or the Contemplated Transactions or any action taken or to be taken by Seller in connection with this Agreement or the Contemplated Transactions. 
 (b) Seller is not in material violation of any applicable Legal Requirement relating to the Purchased Assets or Products which violations,
individually or in the aggregate, would result in a Material Adverse Effect. 
  

	 	3.4	BROKERS OR FINDERS 

 Seller has not incurred any Liability
for brokerage or finders’ fees or agents’ commissions or other similar payments in connection with this Agreement or the Contemplated Transactions. 
  

	 	3.5	ABSENCE OF CHANGE 

 Except as set forth in Schedule 3.5
of Seller’s Disclosure Schedules or as otherwise contemplated in this Agreement or any other Transaction Document, since December 5, 2006, (a) there has not been any transaction or occurrence which has resulted in a Material
Adverse Effect and (b) the Purchased Assets have been owned and operated in the Ordinary Course of Business, and there has not been: 
 (i) any acceptance by Seller or its Affiliates of orders for the sale of Products that were not in the Ordinary Course of Business or that involved a material change in or to the regular price, credit or distribution
policies under such orders; 
  

 10 

 (ii) any sale, assignment, pledge, encumbrance or transfer or material impairment of any
Purchased Asset by Seller or its Affiliates; 
 (iii) to Seller’s Knowledge, any material increase or decrease in the
stocks of Products sold by Seller or its Affiliates, other than in the Ordinary Course of Business; or 
 (iv) any agreement
by Seller or its Affiliates to take any of the actions specified in the foregoing items (i) through (iii). 
  

	 	3.6	TRANSFERRED REGISTRATIONS 

 Except as set forth in
Schedule 3.6 of Seller’s Disclosure Schedules or as indicated in Exhibit 2.1(a)(i): 
 (a) To Seller’s
Knowledge, each of the Transferred Registrations are subsisting, are valid and in full force and effect and are not unenforceable in whole or in part; and 
 (b) To Seller’s Knowledge, each of the Transferred Registrations is in material compliance with all Legal Requirements to maintain and support the Product Registrations for Seller’s sale of Products as sold
by Seller as of the date hereof. 
  

	 	3.7	TRANSFERRED REGISTRATION DATA 

 Except as set forth in
Schedule 3.7 of Seller’s Disclosure Schedules or as indicated in Exhibit 2.1(a)(ii): 
 (a) Seller has not
granted any third party (other than Affiliates of Seller) any right to cite to the Transferred Registration Data; and 
 (b)
To Seller’s Knowledge, the Transferred Registration Data is sufficient to support the Transferred Registrations as of the date hereof. 
  

	 	3.8	TRANSFERRED TRADEMARKS 

 Except as set forth in Schedule
3.8 of Seller’s Disclosure Schedules or as indicated in Exhibit 2.1(a)(iii): 
 (a) Seller has not granted any
third party (other than Affiliates of Seller) any rights in the Transferred Trademarks nor entered into any agreement with any third party in conflict with the transfer of the Transferred Trademarks as contemplated in this Agreement; 
  

 11 

 (b) To Seller’s Knowledge, all of the Transferred Trademarks are valid and
enforceable, and have not been adjudged unenforceable in whole or part; 
 (c) To Seller’s Knowledge, no third party
(other than Affiliates of Seller) is engaging in any activity that infringes upon the use of the Transferred Trademarks; and 
 (d) To Seller’s Knowledge, the use of the Transferred Trademarks associated with the sale of Products does not infringe upon the trademark rights of any Person. 
  

	 	3.9	TRANSFERRED KNOW-HOW 

 Except as set forth in Schedule
3.9 of Seller’s Disclosure Schedules: 
 (a) Seller or its applicable Affiliate owns the Transferred Know-How and has
the right to grant to Buyer the rights granted under the Assignment and Assumption Agreement. Seller has not granted any third party (other than Affiliates of Seller) any rights in the Transferred Know-How in conflict with the terms of the
Assignment and Assumption Agreement. 
 (b) To Seller’s Knowledge, (i) no third party has misappropriated any of the
Transferred Know-How and (ii) none of the Transferred Know-How was misappropriated from any third party. 
 (c) To
Seller’s Knowledge, (i) no written claim or demand of any Person has been made nor is there any Proceeding that is pending, or Threatened, that challenges the rights of Seller in respect of the Transferred Know-How and (ii) none of
the Transferred Know-How is subject to any outstanding order, ruling, decree, judgment or stipulation by or with any court, arbitrator, or administrative agency. 
  

	 	3.10	CLOSING INVENTORY 

 (a) The Closing
Inventory is good and salable and has been maintained in the ordinary course of business. 
 (b) As of the Closing Date the
Closing Inventory will have a remaining shelf-life of not less than one (1) year; 
 (c) Based upon the sales activity of
Seller taken on a product by product basis and averaged over the course of 2004, 2005 and 2006, Seller would typically have been able to sell approximately seventy five percent (75%) of the Closing Inventory (as measured in aggregate dollar
value) within a period of seven (7) months commencing on the Closing. 
 (d) EXCEPT AS OTHERWISE EXPRESSLY SET FORTH
HEREIN, SELLER MAKES NO REPRESENTATIONS OR WARRANTIES WITH RESPECT TO THE CLOSING INVENTORY AND, EXCEPT FOR WARRANTY AS TO TITLE, SPECIFICALLY DISCLAIMS ALL OTHER WARRANTIES EXPRESS OR IMPLIED, INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY AND
FITNESS FOR A PARTICULAR PURPOSE. 
  

 12 

	 	3.11	CONTRACTS/TRANSFERRED CONTRACTS 

 (a)
Except as set forth in Schedule 3.11(a) of Seller’s Disclosure Schedules, there are no contracts relating to the Purchased Assets. 
 (b) Except as set forth in Schedule 3.11(b) of Seller’s Disclosure Schedules, to Seller’s Knowledge, 
 (i) there is no breach or default, or facts that, given the passage of time would result in a breach or default, of any Transferred Contract; 
 (ii) each Transferred Contract is legal, valid and binding; is in full force and effect; and will continue to be so upon consummation of
this transaction. 
  

	 	3.12	FINANCIAL INFORMATION 

 Seller represents and warrants
that, as of the Closing Date, the financial information set forth in Schedule 3.12 of Seller’s Disclosure Schedules, which consists of gross sales and gross margins for each of the Products during calendar year 2007, is true, complete
and accurate for the time period in question and is based upon Seller’s standard accounting practices. Further, the parties agree that Schedule 3.12 of Seller’s Disclosure Schedules shall be provided to Buyer for viewing by Buyer’s
attorney’s eyes only and may not be viewed by any other person in Buyer’s organization unless and until the transaction contemplated hereunder closes. 
  

	4.	REPRESENTATIONS AND WARRANTIES OF BUYER 

 Except as
set forth in Buyer’s Disclosure Schedules, Buyer hereby represents and warrants to Seller as of the date hereof as follows: 
  

	 	4.1	ORGANIZATION; AUTHORITY; NO CONFLICT; CONSENTS 

 (a) Buyer is a corporation duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization. 
 (b) Each of Buyer and its Affiliates has the requisite power and authority to (i) own the Purchased Assets to be purchased by it, (ii) execute and deliver the Transaction Documents to which it is a party and
(iii) consummate the Contemplated Transactions required to be consummated by it. Buyer has duly executed and delivered this Agreement, and this Agreement constitutes the legal, valid and binding obligation of Buyer, enforceable against Buyer in
accordance with its terms, subject to applicable bankruptcy, insolvency and other similar laws affecting the enforceability of creditors’ rights generally, general equitable principles, and court discretion in granting equitable remedies.

  

 13 

 (c) Except as set forth in Schedule 4.1(c) of Buyer’s Disclosure Schedules,
none of Buyer’s execution, delivery nor performance of the Transaction Documents to which it is a party, nor Buyer’s consummation of the Contemplated Transactions, will: 
 (i) result in a violation of any of the constituent documents of Buyer or any resolution currently in effect adopted by the management
organization of Buyer; or 
 (ii) result in a violation or breach of, or constitute (with or without due notice or lapse of
time or both) a default (or give rise to any right of termination, cancellation or acceleration) under, any of the terms, conditions or provisions of any note, bond, mortgage, indenture, lease, license, contract, agreement or other instrument or
obligation to which Buyer is a party or by which it or any of its properties or assets may be bound, excluding from the foregoing clause (ii) such violations, breaches or defaults which would not, individually or in the aggregate, materially
interfere with Buyer’s ability to consummate the Contemplated Transactions; or 
 (iii) violate any order, writ,
injunction, decree or statute, rule or regulation applicable to Buyer or any of its properties or assets, excluding from the foregoing clause (iii) such violations, breaches or defaults which would not, individually or in the aggregate,
materially interfere with Buyer’s ability to consummate the Contemplated Transactions; or 
 (iv) to Buyer’s
knowledge, give any Governmental Body the right to challenge any of the Contemplated Transactions. 
 (d) To Buyer’s
knowledge, except as set forth in Schedule 4.1(d) of Buyer’s Disclosure Schedules, Buyer is not required to give any notice to, or obtain any Consent from any (i) Governmental Body, (ii) Person pursuant to any written Contract
or (iii) management organization, stockholders or members of Buyer, in connection with the Contemplated Transactions. 
  

	 	4.2	LITIGATION; COMPLIANCE WITH LEGAL REQUIREMENTS 

 (a) There are no Proceedings pending or, to Buyer’s knowledge, Threatened, against Buyer, that question the validity of this Agreement or the Contemplated Transactions or any action taken or to be taken by Buyer in connection with this
Agreement or the Contemplated Transactions. 
 (b) Buyer is not in material violation of any applicable Legal Requirement
which violations, individually or in the aggregate, would have a material adverse effect on Buyer’s ability to perform its obligations under this Agreement or consummate the Contemplated Transactions. 
  

	 	4.3	BROKERS OR FINDERS 

 Buyer has not incurred any Liability
for brokerage or finders’ fees or agents’ commissions or other similar payments in connection with this Agreement or the Contemplated Transactions. 
  

 14 

	 	4.4	PAYMENTS OF BUYER 

 Buyer or its Affiliates have sufficient
cash on hand or available borrowing capacity under its existing lines of credit to pay the Purchase Price and the other payments required to be paid by Buyer hereunder as provided herein. 
  

	 	4.5	INSPECTIONS; NO OTHER REPRESENTATIONS 

 Buyer hereby
acknowledges and agrees that, except as expressly provided otherwise in this Agreement, the Purchased Assets are sold “as is” and Buyer agrees to accept, and to cause its applicable Affiliates to accept, the Purchased Assets in the
condition they are in on the Closing Date, except with respect to the Closing Inventory as specifically provided in Section 2.2(c)(i), based on its own inspection, examination and determination with respect to all matters, and Seller makes no
representations or warranties (express or implied) with respect to the Purchased Assets, the Products and/or the Contemplated Transactions, or any matter relating thereto, except as expressly set forth in Article 3 of this Agreement. Buyer hereby
acknowledges and agrees that Seller makes no representation or warranty (express or implied) with respect to (a) any projections, estimates or budgets delivered or made available to Buyer or any of its Affiliates, or Buyer’s or any of its
Affiliates’ counsel, accountants or advisors of future revenues, future results of operations (or any component thereof), future cash flows, future financial condition (or any component thereof), future business or future operations or
(b) any other information or documents delivered or made available to Buyer or any of its Affiliates, or Buyer’s or any of its Affiliates’ counsel, accountants or advisors, with respect to the Purchased Assets, the Products and/or the
Contemplated Transactions, or any matter relating thereto including, without limitation, any information and/or documents delivered or made available during or in connection with Buyer’s or any of its Affiliates’ due diligence, except as
expressly set forth in Article 3 of this Agreement. 
  

	5.	COVENANTS 

  

	 	5.1	COVENANT NOT TO COMPETE 

 After the Closing, for a period
the shorter of (a) five (5) years following the Closing Date or (b) the applicable non-compete periods permitted by Legal Requirements in the applicable jurisdictions, and subject to the limitations below, Seller shall not, and shall
cause its Affiliates not to, sell products containing PCNB other than the Excluded Products. Notwithstanding the foregoing, nothing contained in this Section 5.1 or elsewhere in this Agreement shall prevent Seller or any of its Affiliates from
(i) performing its obligations under any Transaction Document (including, without limitation, any of its obligations under the Transition Agreement) or (ii) marketing and/or selling, directly or indirectly, any of the Products or other
products on behalf of, or to, any of Buyer, its Affiliates or other Persons as mutually agreed by Buyer or its Affiliates and Seller and/or its Affiliates. 
  

	 	5.2	EXECUTION AND DELIVERY OF OTHER TRANSACTION DOCUMENTS 

 At
the Closing, and in addition to entering into and delivering this Agreement, Seller and Buyer shall, and/or shall cause their respective applicable Affiliates to, enter into and deliver the other Transaction Documents required to be entered into and
delivered by such parties at the Closing. 
  

 15 

	 	5.3	ACCESS AND INVESTIGATION/COOPERATION 

 (a)
From and after the Closing, each party agrees to cooperate with and to grant to the other party and their respective employees and representatives, as appropriate, upon reasonable advance notice and during normal business hours, reasonable access to
the other party’s management personnel and such other information and records as appropriate, relating to the Products and the Purchased Assets, in their possession after the Closing and to permit reasonable copying or, where reasonably
necessary, to furnish original documents relating to the Products, the Purchased Assets and the business related thereto for the purposes of (i) any financial reporting or tax matters (including without limitation any financial and tax audits,
tax contests, tax examination, preparation for any tax returns or financial records); (ii) any investigation being conducted by any Government Body involving the Products, the Purchased Assets or the Business related thereto; (iii) any
claims or litigation involving either party or the Purchased Assets or the business related thereto; (iv) any matters related to registrations of Products; or (v) any similar or related matter. Each party shall use its commercially
reasonable efforts to ensure that its access to and requests for records and documents pursuant to this Section 5.3(a) are conducted so as not to interfere with the normal and ordinary operation of the other party’s business. Each
party acknowledges that the records and documents made available to such party pursuant to this Section 5.3(a) constitute confidential information of the releasing party and shall be treated accordingly, and further, that the cost of responding
to any request under this Section 5.3(a) shall be borne solely by the requesting party. 
 (b) Subject to the terms and
conditions herein provided, each of the parties hereto agrees to, both prior to and after the Closing, use all commercially reasonable efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper or
advisable to consummate and make effective as promptly as practicable the transactions contemplated by this Agreement and to cooperate with each other and to keep each other informed in connection with the foregoing, including using all commercially
reasonable efforts (i) to obtain all necessary waivers, consents and approvals from other parties, (ii) to obtain all necessary consents, approvals and authorizations as are required to be obtained under any federal, state or foreign law
or regulations, (iii) to effect all necessary registration transfers, and (iv) to fulfill all conditions to this Agreement. Seller shall, at any time from and after the Closing, upon the request of Buyer and at Buyer’s expense, do,
execute, acknowledge and deliver, and cause to be done, executed, acknowledged and delivered, all such further acts, assignments, transfers, conveyances, powers of attorney or assurances as may be reasonably required to transfer, convey, grant and
confirm to and vest in Buyer good title to all of the Purchased Assets, free and clear of all liens. 
 (c) Buyer agrees to
deliver promptly to Seller any amounts received by or on behalf of Buyer that are clearly identifiable as pre-Closing accounts receivable from the sale of Products by the Seller and Seller agrees to deliver promptly to Buyer any amounts received by
or on behalf of Seller that are clearly identifiable as post-Closing accounts receivable from the sale of Products by the Buyer. 
  

 16 

	 	5.4	PRODUCT REGISTRATIONS 

 (a) Seller shall
cause the Transferred Registrations to be transferred to Buyer in its or its designated Affiliates’ name(s) as soon as is reasonably practicable after the Closing. Any and all fees, expenses and other costs associated with effectuating such
transfers shall be borne by Buyer and/or its Affiliates and none of Seller nor its Affiliates shall be responsible for the payment of such fees, expenses or costs. In furtherance of effectuating such transfers, Buyer shall, promptly after the
Closing, commence the filing of all applications, documents, and supporting information with all applicable Governmental Bodies that are necessary or appropriate to effectuate such transfers and complete such filings within ninety (90) days
after the Closing, and shall diligently prosecute the effectuation of such transfers. Upon receipt of approvals from the appropriate Governmental Bodies regarding a transfer of a Transferred Registration, Buyer and its Affiliates shall comply
with all Legal Requirements for changeover of all Product packaging, labeling, and package inserts associated with the Products that are the subject of such Transferred Registration. Notwithstanding anything herein to the contrary and, subject to
compliance with applicable Legal Requirements, except for such inventory of Products existing at the time the appropriate Governmental Body approves the transfer of a Transferred Registrations for a Product, (i) commencing with the first
production run after the appropriate Governmental Body approves the transfer of a Transferred Registration for a Product, Buyer and its Affiliates shall use Buyer’s and its Affiliates’ approved packaging, labeling, and package inserts for
such Product and cease using Seller’s or its Affiliates’ packaging, labeling, and package inserts for such Product and (ii) in any event, no later than six (6) months from the date the appropriate Governmental Body approves a
transfer of a Transferred Registration for a Product, Buyer and its Affiliates shall change the labels on and package inserts included with all such Product produced after such approval to Buyer’s and its Affiliates’ approved labels and
package inserts and in accordance with all Legal Requirements, and shall remove Seller’s name and telephone numbers from all labeling, package inserts, and other Product supporting materials and information associated with such Product
including, but not limited to, material safety data sheets. Buyer and its Affiliates shall only use Seller’s or its Affiliates’ packaging, labeling, and package inserts for a Product in a manner consistent with Legal Requirements. Until
the transfer of Transferred Registrations has been completed, Seller shall take all actions reasonably necessary to permit Buyer to manufacture, market, sell, and distribute Products in reliance upon Seller’s Transferred Registrations and the
underlying data. 
 (b)(i) Seller shall, and shall cause its Affiliates to, provide reasonable assistance to Buyer and its
Affiliates in seeking to have the Transferred Registrations transferred to Buyer and/or its Affiliates and (ii) until the transfer of the Transferred Registrations to Buyer and/or its Affiliates has been effected, Seller shall take reasonable
actions to maintain the Transferred Registrations that have not yet been transferred to Buyer and shall not make any modifications to the Transferred Registrations without the prior written consent of Buyer (such consent not to be unreasonably
withheld or delayed); provided, however, that Buyer shall reimburse Seller and its Affiliates for any and all out-of-pocket fees, expenses and other costs incurred by Seller and its Affiliates in connection with such assistance and/or actions upon
demand therefor. 
  

 17 

	 	5.5	CONFIDENTIALITY 

 This Agreement, the Transaction Documents
and the Exhibits hereto and thereto and any information disclosed by one party to the other party and identified as “confidential” or similar notation, or any information which is developed by the parties in cooperation with each other, in
connection with the Contemplated Transactions (such information, “Confidential Information”) shall, except as otherwise permitted by this Agreement, be maintained in confidence by the parties, and used only for the purposes
of this Agreement. Except as otherwise permitted by this Agreement or the other Transaction Documents, a party shall not disclose the Confidential Information of the other party to any third party without the prior written permission of the other
party for a period of ten (10) years after the termination of this Agreement or the other Transaction Documents, as the case may be; provided that the foregoing obligation of confidentiality shall not extend to information that is: 

(a) already known at the time of its receipt by the receiving party; 
 (b) property in the public domain through no fault of the receiving party; 
 (c) disclosed to the receiving party by a third party who may lawfully do so; or 
 (d) required to be disclosed by the receiving party to any Governmental Body, and not subject to protection as confidential business
information or otherwise protected by statute or common law privilege against disclosure; provided, however, that prior to any such disclosure to any Governmental Body, the receiving party shall allow the other party reasonable time to take such
steps as to limit such disclosure. 
 Notwithstanding the foregoing, (i) a party may disclose Confidential Information to its Affiliates, consultants
and attorneys having a need to know and who are subject to a confidentiality agreement at least as strict as this Section 5.5 and (ii) nothing contained in this Section 5.5 or elsewhere in this Agreement shall prevent or limit Seller
and its Affiliates from disclosing information to third parties to the extent necessary or desired in connection with the transfer and assignment of the Purchased Assets (including, without limitation, the Transferred Contract) to Buyer or its
Affiliates as contemplated in this Agreement. 
  

	 	5.6	PUBLICITY 

 No public release or announcement concerning
this Agreement, any other Transaction Document or the Contemplated Transactions shall be issued by either party without the prior written consent of the other party, except to the extent such release or announcement may be required by a Legal
Requirement or the rules or regulations of any U.S. or foreign securities exchange, in which case the releasing party shall allow the other party reasonable time to comment on such release or announcement in advance of its issuance. 
  

 18 

	 	5.7	TRANSFER TAXES 

 (a) All transfer,
documentary, sales, use, value added, goods and services, registration and other taxes, but not Seller’s income taxes, and related fees (including any penalties, interest and additions to tax) incurred in connection with this Agreement, any
other Transaction Document and/or the Contemplated Transactions shall be paid by Buyer. Seller and Buyer shall cooperate in a timely manner in making all such filings, returns, reports and forms as may be required to comply with the provisions of
all tax laws with respect to such taxes. 
 (b) To the extent Buyer is required by any applicable income tax law to withhold a
portion of the payment owing to Seller hereunder, Seller shall accept the resulting net payment as due performance. Buyer shall, however, take all commercially reasonable steps necessary to secure the benefit of any reduction of withholding tax rate
available under treaty and shall promptly provide Seller with a receipt for any tax withheld. Receipts should be sent to Seller’s address as set forth in Section 7.2 hereof. 
  

	 	5.8	CERTAIN DOCUMENTS 

 Upon the request of a party, the other
party shall, and shall cause its Affiliates to, execute, deliver and file, after good faith discussions, any and all agreements and other documents reflecting or incorporating all or any of the provisions contained in this Agreement to the extent
such execution, delivery and/or filing is required by, or supports compliance with, any applicable Legal Requirement, or is otherwise necessary, to effect the transfer of the Purchased Assets from Seller (or its Affiliates) to Buyer (or its
Affiliates) as provided in this Agreement; provided, however, that nothing contained in such agreements and documents shall modify any of the provisions contained in this Agreement and in the event of a conflict between any provision contained in
such agreement or documents and any provision contained in this Agreement, then the provision contained in this Agreement shall control. 
  

	 	5.9	POST-CLOSING DOCUMENTS/ASSIGNMENTS 

 Promptly after the
Closing, Seller shall provide Buyer with (a) copies of all Transferred Contracts, (b) copies of all agreements that are not Transferred Contracts that are in effect as of the Closing and relate to the tolling or formulation of Products,
and (c) Seller’s production schedule for the Products for 2008. Seller agrees to facilitate the assignment of all Transferred Contracts to Buyer, which assignment, and the assumption of such Transferred Contracts by Buyer, shall be
memorialized in an amendment to the Assignment and Assumption Agreement. In the event that Buyer elects not to seek assignment of one or more Transferred Contracts or if any of the Transferred Contracts requires the consent of the counter-party
thereto to assign such Transferred Contract and such counter-party refuses to give such consent, then Buyer and Seller will cooperate to enable Buyer to receive the benefit of such Transferred Contract and to enable Seller to comply with its
obligations thereunder. Such cooperation will include, but is not limited to, Seller, at Buyer’s request, administering such Transferred Contract so that Buyer receives the benefit thereof and (y) Buyer facilitating Seller’s
performance under such Transferred Contract by, in the case of any such Transferred Contract that provides for the production of finished goods Products for Seller, purchasing such finished goods Products from Seller at Seller’s cost or, in the
case of any such Transferred Contract that provides for the sale of finished goods Products, selling such Products to Seller so that it may re-sell them to the Transferred Contract counter-party in accordance with the terms of the Transferred
Contract. In the event of any such resale of such Products by Seller, Seller shall pay over to Buyer the profit 

  

 19 

 
enjoyed upon such resale, less an administration fee equal to 2% of Seller’s price charged to the Transferred Contract counter-party. Seller and Buyer
shall cooperate in the same manner with respect to the Distribution Agreement disclosed in Seller’s Disclosure Schedule 3.11(a), which is not assignable to Buyer because it includes a number of products that are not Products. Seller’s
rights and obligations under this Section 5.9 shall be deemed not to breach Seller’s obligations under Section 5.1 hereof. 
  

	 	5.10	POST-CLOSING SUPPLY AGREEMENTS 

 Promptly after Closing,
Seller and Buyer (and/or their applicable Affiliates) shall execute and deliver agreements providing for the supply of technical grade PCNB by Buyer to Seller (and/or its applicable Affiliates) for use in production of the Excluded Products and for
the supply of technical grade etridiazole by Seller to Buyer (and/or applicable Affiliates) for use in the Products. 
  

	6.	INDEMNIFICATION; REMEDIES 

  

	 	6.1	INDEMNIFICATION AND PAYMENT OF DAMAGES BY SELLER 

 Seller
shall indemnify and hold harmless Buyer and its directors, officers, employees, stockholders, members and Affiliates (collectively, the “Buyer Indemnified Persons”) for, and shall pay to each Buyer Indemnified Person the
amount of, any Liabilities and/or judgments (collectively, “Damages”) actually incurred by such Buyer Indemnified Person, arising from (a) any Breach by Seller of any representation or warranty made by Seller in this
Agreement, (b) any Breach by Seller of any covenant or obligation of Seller in this Agreement or (c) any Excluded Liability. 
  

	 	6.2	INDEMNIFICATION AND PAYMENT OF DAMAGES BY BUYER 

 Buyer
shall indemnify and hold harmless Seller and its directors, officers, employees, stockholders, members and Affiliates (collectively, the “Seller Indemnified Persons”) for, and shall pay to each Seller Indemnified Person the
amount of, any Damages actually incurred by such Seller Indemnified Person arising from (a) any Breach by Buyer of any representation or warranty made by Buyer in this Agreement, (b) any Breach by Buyer of any covenant or obligation of
Buyer in this Agreement or (c) any Assumed Liability. 
  

	 	6.3	SURVIVAL; TIME LIMITATIONS 

 All representations and
warranties of Seller and Buyer in this Agreement shall each survive the Closing and terminate and expire on the date that is fifteen (15) months after the Closing. The indemnification obligations under Sections 6.1(a) and 6.2(a) shall survive
the Closing and expire on the date that is fifteen (15) months after the Closing Date. The indemnification obligations under Sections 6.1(c) and 6.2(c) shall each survive the Closing until the expiration of the applicable statute of limitations
with respect to the indemnification claim being asserted. The indemnification obligations under Section 6.1(b) and 6.2(b) shall survive without limitation. 
  

 20 

	 	6.4	LIMITATIONS ON DAMAGES 

 (a)(i) Seller
shall not be liable under Section 6.1 for an indemnification claim with respect to any individual item or occurrence unless and until the amount of all Damages claimed with respect to such item or occurrence exceeds *** (the “Threshold
Amount”) and all Damages individually exceeding the Threshold Amount exceed, in the aggregate, *** (the “Basket”), whereupon Seller shall only be liable for the amount of such Damages in excess of the Basket and
(ii) notwithstanding anything contained in this Agreement to the contrary, (A) Seller’s total and aggregate liability for all claims under Section 6.1 shall in no event exceed *** and (B) in no event shall a Buyer
Indemnified Person be entitled to indemnification under Section 6.1 if any Buyer Indemnified Person had knowledge of the facts or circumstances giving rise to the claim for indemnification under Section 6.1 prior to the Closing.

 (b) Notwithstanding any other provision in this Agreement or any other Transaction Document to the contrary, Buyer
acknowledges and agrees that its and any Buyer Indemnified Person’s sole and exclusive remedies with respect to any and all claims against Seller or its Affiliates relating to any of this Agreement or any other Transaction Document, the
Purchased Assets or the Contemplated Transactions shall be pursuant to the indemnification provisions set forth in this Article 6. 
 (c) NOTWITHSTANDING ANYTHING CONTAINED HEREIN TO THE CONTRARY, NO INDEMNIFYING PERSON SHALL HAVE ANY OBLIGATION TO INDEMNIFY ANY INDEMNIFIED PERSON FOR LOST PROFITS OR FOR CONSEQUENTIAL, INCIDENTAL, PUNITIVE OR EXEMPLARY DAMAGES UNDER THIS
AGREEMENT. Buyer agrees that it shall not set-off or apply any Damages or other payment obligations owed by Seller to Buyer under this Agreement or any other Transaction Document against any amounts owed by Buyer to Seller under this Agreement, any
other Transaction Document or any other agreement. 
  

	 	6.5	PROCEDURE FOR INDEMNIFICATION-THIRD-PARTY CLAIMS 

 (a) Promptly after receipt by an Indemnified Person under Sections 6.1 or 6.2 hereof of notice of the commencement or Threatened commencement of any third party Proceeding against it (a “Third-Party Claim”), such
Indemnified Person shall, if a claim is to be made against a Person (the “Indemnifying Person”) under Sections 6.1 or 6.2, give written notice of sufficient detail to the Indemnifying Person of the assertion of such
Third-Party Claim. 
 (b) If any Third-Party Claim is brought against an Indemnified Person, the Indemnifying Person shall be
entitled to participate in such Third-Party Claim and, to the extent that it may elect, to assume the defense of such Third-Party Claim with counsel reasonably satisfactory to the Indemnified Person. In such event, the Indemnifying Person will not,
so long as it maintains such defense, be liable to the Indemnified Person under Sections 6.1 or 6.2, as applicable, for any fees of other counsel with respect to the defense of such Proceeding. An election to assume the defense of a Third-Party
Claim shall not be deemed to be an admission that the Indemnifying Person is liable to the Indemnified Person in respect of such Third-Party Claim or that the claims made in the Third-Party Claim are within the scope of or subject to indemnification
under Sections 6.1 or 6.2, as applicable. Should the Indemnifying Person 

  

 21 

 
assume the defense of a Third-Party Claim, the Indemnified Person shall have the right to participate in the defense thereof, including attending meetings,
conferences, teleconferences, settlement negotiations and other related events (and to employ counsel at its own expense in connection therewith); provided, it being understood that the Indemnifying Person shall control the defense of such
Third-Party Claim. If the Indemnifying Person assumes the defense of any such Third-Party Claim, the Indemnified Person shall cooperate, as reasonable, with the Indemnifying Person in the defense of such Third-Party Claim. Without the Indemnifying
Person’s prior written consent, which shall not be unreasonably withheld or delayed, no Indemnified Person may settle or compromise any Third-Party Claim or consent to the entry of any judgment for which the Indemnified Person is seeking
indemnification under Sections 6.1 or 6.2, as applicable, unless the Indemnifying Person fails to assume and maintain the defense of such Third-Party Claim pursuant to this Section 6.5(b). In the event that it is ultimately determined that the
Indemnifying Person is not obligated to indemnify, defend or hold harmless the Indemnified Person in connection with any Third-Party Claim, the Indemnified Person shall promptly reimburse the Indemnifying Person for any and all reasonable costs and
expenses (including reasonable attorney’s fees and court costs) incurred by the Indemnifying Person in its defense of such Third-Party Claim. 
  

	 	6.6	PROCEDURE FOR INDEMNIFICATION-OTHER CLAIMS 

 In the event
any Indemnified Person shall have a claim for indemnification for any matter not involving a Third-Party Claim, the Indemnified Person shall promptly deliver written notice of such claim to the Indemnifying Person, specifying with reasonable
particularity the claim and the basis therefor. 
  

	 	6.7	NET RECOVERY; MITIGATION; ETC. 

 The amount of any Damages
for which indemnification is provided under Sections 6.1 or 6.2, as applicable, shall be net of (a) any amounts recovered by the Indemnified Person pursuant to any indemnification by, or indemnification agreement with, any third party who has
brought any such claim or demand, (b) any insurance proceeds or other cash receipts or sources of reimbursement received from a third party as an offset against or otherwise covering such Damages (each source named in clauses (a) and (b),
a “Collateral Source”) and (c) an amount equal to the present value of the tax benefit, if any, available to or taken by the Indemnified Person attributable to such Damages. If the amount to be netted hereunder from any
payment required under Sections 6.1 or 6.2, as applicable, is determined after payment by the Indemnifying Person of any amount otherwise required to be paid to an Indemnified Person pursuant to this Article 6, the Indemnified Person shall repay to
the Indemnifying Person, promptly after such determination, any amount that the Indemnifying Person would not have had to pay pursuant to this Article 6 had such determination been made at the time of such payment by the Indemnifying Person. The
parties shall take and shall cause their Affiliates to take all reasonable steps to mitigate any Damages for which indemnification is provided under Sections 6.1 or 6.2, as applicable, upon becoming aware of any event that would reasonably be
expected to, or does, give rise to such Damages. Indemnification under this Article 6 shall not be available to any Indemnified Person unless the Indemnified Person first uses all reasonable efforts to seek recovery from all Collateral Sources. The
Indemnifying Person may require the Indemnified Party to assign to the Indemnifying Party the rights to seek recovery pursuant to the 

  

 22 

 
preceding sentence and if any Indemnified Person is indemnified for any Damages pursuant to this Agreement with respect to any Third-Party Claim, then the
Indemnifying Person will be subrogated to all rights and remedies of the Indemnified Person against any and all third parties with respect to such Third-Party Claim, and the Indemnified Person will, and will cause its Affiliates to, cooperate with
and assist the Indemnifying Person in asserting all such rights. 
  

	7.	GENERAL PROVISIONS 

  

	 	7.1	EXPENSES 

 Except as otherwise expressly provided in this
Agreement, each party to this Agreement will bear its respective expenses incurred in connection with the preparation, execution and performance of this Agreement and the Contemplated Transactions, including all fees and expenses of agents,
representatives, counsel and accountants. 
  

	 	7.2	NOTICES 

 All notices, consents, waivers, and other
communications under this Agreement must be in writing and will be deemed to have been duly given when (a) delivered by hand (with written confirmation of receipt), (b) sent by facsimile (with written confirmation of receipt) or other
electronic means; provided that a hard copy is mailed by registered mail, return receipt requested promptly thereafter or (c) when received by the addressee, if sent by a nationally recognized overnight delivery service (receipt requested), in
each case to the appropriate addresses and facsimile numbers set forth below (or to such other addresses and facsimile numbers as a party may designate by notice to the other parties): 
 If to Seller: 
 Chemtura Corporation

 199 Benson Road 
 Middlebury,
CT 06749 
 Attention: General Counsel 
 Facsimile: (203) 573-4301 
 If to Buyer: 
 AMVAC Chemical Corporation 
 4695 MacArthur Court, Suite 1250 
 Newport Beach, CA 92660 
 Attention: Sr. V.P.
Business Development 
 Facsimile: 949.260.1201 
  

 23 

 With a copy to: 
 Timothy J. Donnelly, Esq. 
 timd@amvac-chemical.com 
 Facsimile: 949.260.1215 
  

	 	7.3	DISPUTE RESOLUTION; GOVERNING LAW; JURISDICTION 

 (a) Any dispute between the parties arising out of or relating to this Agreement or the Contemplated Transactions, or the interpretations, validity or effectiveness of this Agreement, or any provision of this Agreement, in the event the
parties fail to agree, shall, upon the written request of a party, be referred to designated senior management of representatives of the parties for resolution. Such representatives shall promptly meet and, in good faith, attempt to resolve the
controversy, claim or issues referred to them. 
 (b) If such representatives do not resolve the dispute within thirty
(30) calendar days after the dispute is referred to them, the dispute shall be resolved through mediation before a mediator of the parties’ mutual choosing. In the event that the parties are unable to resolve such dispute through mediation
within ninety (90) days after first notice thereof, then either party may institute legal proceedings (as per the provisions set forth in the immediately following paragraph). Notwithstanding anything in the foregoing to the contrary, in the
event that a party would be materially adversely affected by submitting a matter to mediation (e.g., in the event of a claim that requires immediate equitable relief), such party may bring such claim before a court without first resorting to
mediation. 
 (c) This Agreement shall be governed by the substantive laws of the State of Delaware without regard to its
conflicts of laws principles, and, except as otherwise provided herein, exclusive jurisdiction over any proceeding seeking to enforce any provision of, or based upon any right arising out of, this Agreement or the Contemplated Transactions, shall be
in (x) the State and Federal courts in the Orange County, California to the extent that the matter is instituted by Seller, and (y) the State and Federal courts of Connecticut , to the extent that the matter is instituted by Buyer. The
parties hereto do hereby irrevocably (i) submit themselves to the personal jurisdiction of such courts, (ii) agree to service of such courts’ process upon them with respect to any such proceeding, (iii) waive any objection to
venue laid therein and (iv) consent to service of process by registered mail, return receipt requested. 
 (d) The
parties acknowledge and agree that the foregoing choice of law and forum provisions are the product of an arms-length negotiation between the parties. 
  

	 	7.4	NO IMPLIED WAIVERS; NO JURY TRIAL 

 Except as otherwise set
forth herein, the rights and remedies of the parties to this Agreement are cumulative and not alternative. Neither the failure nor delay by any party in exercising any right, power or privilege under this Agreement or the documents referred to in
this Agreement will operate as a waiver of such right, power or privilege, and no single or partial exercise of any such right, power or privilege will preclude any other or further exercise of such 

  

 24 

 
right, power or privilege or the exercise of any other right, power or privilege. Each party hereby waives to the fullest extent allowed under law, any right
it may have to a trial by jury in respect of any litigation directly or indirectly arising out of, under or in connection with this Agreement or any of the Contemplated Transactions. 
  

	 	7.5	ENTIRE AGREEMENT AND MODIFICATION 

 This Agreement
supersedes all prior agreements between the parties with respect to its subject matter and constitutes (along with the documents referred to in this Agreement) a complete and exclusive statement of the terms of the agreement between the parties with
respect to its subject matter. This Agreement may not be amended except by a written agreement executed by Buyer and Seller. Any items listed, set forth, described or otherwise disclosed on or in any part of this Agreement, Seller’s Disclosure
Schedules or the exhibits hereto shall be deemed listed, set forth, described and otherwise disclosed on or in all other parts of this Agreement, Seller’s Disclosure Schedules and the exhibits hereto. 
  

	 	7.6	ASSIGNMENTS, SUCCESSORS, AND NO THIRD-PARTY RIGHTS 

 Neither party may assign any of its rights under this Agreement without the prior written consent of the other party, such consent not to be unreasonably withheld or delayed. Notwithstanding the foregoing, either party may assign or
transfer this Agreement to (a) an Affiliate or (b) a third party to which such party has transferred substantially all of its assets; provided, however, that such transferee shall be bound by all of the terms and conditions of this
Agreement. This Agreement will apply to, be binding in all respects upon and inure to the benefit of the successors and permitted assigns of the parties. Unless otherwise expressly provided herein, nothing expressed or referred to in this Agreement
will be construed to give any Person other than the parties to this Agreement any legal or equitable right, remedy or claim under or with respect to this Agreement or any provision of this Agreement. This Agreement and all of its provisions and
conditions are for the sole and exclusive benefit of the parties to this Agreement and their successors and permitted assigns. 
  

	 	7.7	SEVERABILITY 

 If any provision of this Agreement, other
than any obligation to pay money, is held invalid or unenforceable by any court of competent jurisdiction, the other provisions of this Agreement will remain in full force and effect. Any provision of this Agreement held invalid or unenforceable
only in part or degree will remain in full force and effect to the extent not held invalid or unenforceable. 
  

	 	7.8	SECTION HEADINGS; CONSTRUCTION 

 The headings of Articles
and Sections in this Agreement and the Disclosure Schedules attached hereto are provided for convenience only and will not affect its construction or interpretation. All references to “Article” or “Articles” and
“Section” or “Sections” refer to the corresponding Article or Articles and Section or Sections of this Agreement. All words used in this Agreement will be construed to be of such gender or number as the circumstances require.
Unless otherwise expressly provided, the word “including” does not limit the preceding words or 

  

 25 

 
terms. The parties hereto acknowledge and agree that (a) each party and its counsel have reviewed and negotiated the terms and provisions of this
Agreement and have contributed to its revision, (b) the rule of construction to the effect that any ambiguities are resolved against the drafting party shall not be employed in the interpretation of this Agreement and (c) the terms and
provisions of this Agreement shall be construed fairly as to all parties hereto, regardless of which party was generally responsible for the preparation of this Agreement. 
  

	 	7.9	TIME OF THE ESSENCE 

 With regard to all dates and time
periods set forth or referred to in this Agreement, the parties hereto agree that time is of the essence. 
  

	 	7.10	COUNTERPARTS 

 This Agreement may be executed in any number
of counterparts, each of which will be deemed to be an original copy of this Agreement and all of which, when taken together, will be deemed to constitute one and the same agreement. 
 [signature page follows] 
  

 26 

 IN WITNESS WHEREOF, the parties have executed and delivered this Agreement as of the date first above
written. 
  

			
	SELLER:
	
	CHEMTURA CORPORATION
		
	By:	 	 
	Name:	 	 
	Title:	 	 
	
	BUYER:
	
	AMVAC CHEMICAL CORPORATION
		
	By:	 	 
	Name:	 	 
	Title:Asset Purchase and Sale Agreement

 EXHIBIT 10.10 
 ASSET PURCHASE AGREEMENT 
 FOR THE ACQUISITION OF 
 CERTAIN ASSETS 
 OF 

VALENT U.S.A. CORPORATION 
 DECEMBER 27, 2007 

 ASSET PURCHASE AGREEMENT 
 THIS ASSET PURCHASE AGREEMENT (this Agreement”) is made and entered into as of December 27, 2007, (the “Effective
Date”), by and among VALENT U.S.A. CORPORATION, a California corporation having a place of business at 1600 Riviera Avenue, Suite 200, Walnut Creek, CA 94596 (hereinafter referred to as “VALENT”) and AMVAC Chemical Corporation, 4695
MacArthur Court, Suite 1250, Newport Beach, California 92660 (hereinafter referred to as “PURCHASER”). VALENT and PURCHASER are hereinafter referred to collectively as the “Parties” and individually as a “Party”.

 WITNESSETH 
 WHEREAS, VALENT is the owner of certain assets specifically, the “Acephate Assets” as defined in Section 2.1 below relating to the insecticide Acephate (O, S-Dimethyl acetylphosphoramidothiate) marketed in the United
States under the end use product name ORTHENE; and 
 WHEREAS, VALENT desires to sell and transfer to PURCHASER and PURCHASER desires
to acquire the Acephate Assets upon the terms and subject to the conditions set forth herein. 
 NOW, THEREFORE, in consideration of
the premises and the mutual representations, warranties and covenants and agreements contained herein, the receipt and sufficiency of which are hereby acknowledged, and upon and subject to the terms and the conditions hereinafter set forth, the
Parties do hereby agree as follows: 
 ARTICLE 1 - DEFINITIONS 
 As used in this Agreement, the following terms shall have the following meanings: 
 1.1 “Acephate
Agricultural Products” means those products identified in Schedule 1.1 below. 
 1.2 “Acephate Assets” means each and all of
the items set forth in Section 2.1 below. 
 1.3 “Acephate Professional Products” means those products identified in Schedule
1.3 below. 

 1.4 “Acephate Products” or
“Products” means collectively Acephate Agricultural Products and Acephate Professional Products having Acephate as an active ingredient and sold under the brand name Orthene®.

 1.5 “Acephate Technical” means and is defined by the EPA Confidential Statement of Formula (CSF). 
 1.6 “Active Ingredient” means the active ingredient Acephate (O, S-Dimethyl acetylphosphoramidothiate). 
 1.7 “Books and Records” means all books and records relating primarily to the Acephate Assets, including books of account. 
 1.8 “Closing” means the consummation of the sale and purchase of the Acephate Assets and of the transactions contemplated hereby. 

1.9 “Closing Date” means the date on which the Closing takes place. 
 1.10 “Data” means documents, research, data, studies and other materials identified on Schedule 1.10 submitted by VALENT in support of the EPA
Registrations or the State Registrations. 
 1.11 “Data Compensation” means all rights to compensation by third parties pursuant to
Section 3(c)(1)(D) of the Federal Insecticide, Fungicide and Rodenticide Act for Data . 
 1.12 “Effective Date” means the
date recited in the first paragraph of the preamble of the Agreement. 
 1.13 “EPA” means the United States Environmental
Protection Agency. 
 1.14 “EPA Registrations” means all those EPA Registrations including Special Local Need (“SLN”,
24(c) and 2(ee) registrations identified in Schedule 1.14 for the Active Ingredient, Acephate Technical and the registration thereof in the United States, Reg. No. 59639-41 and the end use products, identified in Schedules 1.1 and 1.3 below.

 1.15 “Finished Goods” means all saleable packaged formulated Acephate Products owned by VALENT 
 1.16 “Formulations” means a mixture of Acephate Technical and inert ingredients resulting in Acephate Products. 
  

 - 2 - 

 1.17 “Governmental Authority” means any nation or government, any state or other political
subdivision thereof, any legislative, executive or judicial unit or instrumentality of any Governmental Authority (foreign, federal, state or local) or any department, commission, board, agency, bureau, official or other regulatory, administrative
or judicial authority thereof or any entity (including a court) exercising executive, legislative, judicial, tax, regulatory or administrative functions of or pertaining to government or any self-regulatory organization. 
 1.18 “Inventory” means collectively all unformulated Acephate Technical, Inert Raw Materials, Packaging Supplies and all Finished Goods owned
by VALENT on the Closing Date. 
 1.19 “Material Adverse Effect” means any change, event, circumstance or development, individually
or when taken together with all other such similar or related changes, events, circumstances or developments, that (i) has a material adverse effect on the Acephate Assets, or (ii) prevents or delays the ability of VALENT to consummate the
transactions contemplated by this Agreement or any of the ancillary documents or agreements to be delivered in connection herewith, other than (A) effects due to general economic conditions or matters generally affecting the industry in which
VALENT operates and which do not materially disproportionately impact VALENT when compared to other businesses operating in the same industry, (B) effects which result from the loss of customers or an adverse effect on customers’ requests
for VALENT’s goods and services, which, in either case, is directly attributable to the announcement or occurrence of this Agreement and the transactions contemplated hereby, (C) effects which result from liabilities incurred in connection
with this Agreement or the transactions contemplated hereby or (D) effects resulting from VALENT’s compliance with the terms of, or the taking of any action contemplated by or permitted by, this Agreement. 
 1.20 “Orthene® Trademark”
means the trademark ORTHENE for use in the United States on Acephate Products sold by VALENT for commercial uses exclusively licensed to VALENT by The Scotts Company and its affiliate OMS Investments, Inc. (as successor-in-interest to Chevron
Chemical Company) pursuant to the Trademark License Agreement dated September 16, 1991 between Chevron Chemical Company and VALENT 
 1.21 “Packaging Supplies” means all packaging materials such as bags, cartons, and measuring devices, used for packaging Acephate Products. 
  

 - 3 - 

 1.22 “Proprietary Information” means all existing trade secrets, know-how, recipes, product
formulations, processing procedures and other proprietary information used in the conversion of Acephate Technical to Finished Goods and, Finished Goods specifications relating exclusively to the Acephate Products. 
 1.23 “Patent Rights” means VALENT’s interest in the patents identified on Schedule 1.23 attached and incorporated by reference herein.

 1.24 “Raw Materials” means Acephate Technical and all inert ingredients used to formulate Acephate Products. 
 1.25 “State Registrations” means those state registrations identified on Schedule 1.25. 
 1.26 “Studies” means all archived study materials whether conducted under good laboratory practices (GLP) or not including paper and electronic
data, blocks, slides and test materials conducted by or on behalf of VALENT of or related specifically to the Products along with wet tissues as identified on Schedule 1.26. 
 1.27 “Taxes” means any net income, alternative or add-on minimum tax, gross income, gross receipts, sales, use, ad valorem, value added,
transfer, franchise, profits, license, withholding on amounts paid to or VALENT, payroll, employment, excise, severance, stamp, occupation, premium, property, escheat, environmental or windfall profit tax, custom, duty or other tax, governmental fee
or other like assessment or charge of any kind whatsoever, together with any interest or any penalty, addition to tax or additional amount imposed by any federal, state, local, county or foreign taxing authority. 
 1.28 “Technical and Market Information” means all transferable technical and market information relating to the formulation, use and sale of
the Active Ingredient and Products owned by and in the possession of VALENT or an agent of VALENT, such Technical and Market Information to include without limitation the Studies and available customer information previously disclosed by VALENT to
PURCHASER under the Confidentiality Agreement dated July 27, 2007 and executed by PURCHASER on August 1, 2007 identified in Schedule 1.28 below. 
 1.29 “Trademark Rights” means VALENT’s trademarks owned or licensed by VALENT and identified on Schedule 1.29 below. 
  

 - 4 - 

 1.30 “Transferred Contracts” means those contracts to be transferred to PURCHASER hereunder as
identified on Schedule 7.13 below. 
 ARTICLE 2 – PURCHASE AND SALE OF ASSETS. 
 2.1 Purchase and Sale of Acephate Assets. Upon the terms and subject to the conditions of this Agreement, PURCHASER shall purchase from VALENT, and
VALENT shall sell, transfer, convey, and deliver to PURCHASER at the Closing, the Acephate Assets for the consideration specified in Section 4.1. The Acephate Assets shall include the following: 
  

	 	(a)	Technical and Market Information, including existing customer lists and EDI data for the past five (5) years; 

  

	 	(b)	EPA Registrations and State Registrations of Acephate Technical, and the Acephate Products; 

  

	 	(c)	Data; 

  

	 	(d)	Inventory as of the Closing Date; 

  

	 	(e)	Finished Goods; 

  

	 	(f)	All right, title and interest in the Patent Rights; 

  

	 	(g)	All right, title and interest in the Trademark Rights; 

  

	 	(h)	All right, title and interest in the Studies; 

  

	 	(i)	Except as otherwise provided herein, all right, title and interest in the right to receive Data Compensation by third parties for Acephate; 

  

	 	(j)	All Books and Records relating to the Acephate Products; 

  

	 	(k)	All Proprietary Information; 

  

	 	(l)	Third Party Contracts, and 

  

	 	(m)	Unfilled Customer Purchase Orders for Acephate products for delivery following the Closing Date. 

  

 - 5 - 

 2.2 Excluded Assets. Notwithstanding anything herein to the contrary, the Assets shall not include
the following assets, properties and/or rights (the “Excluded Assets”), which shall remain the property of VALENT after the Closing: 
  

	 	(a)	all personnel records and other records that VALENT is required by law to retain in its possession; 

  

	 	(b)	all claims for the refund of Taxes (as defined herein) and other governmental charges of whatever nature; 

  

	 	(c)	all rights in connection with and assets of VALENT’s Employee Benefit Plans; 

  

	 	(d)	all rights of VALENT under this Agreement and ancillary agreements/instruments; 

  

	 	(e)	the property and assets listed on Schedule 2.2(e) which would include cash, time deposits, CDs, cash equivalents and accounts owned by VALENT; VALENT’s trademarks, service
marks, logos, internet domains and applications, other than the Trademarks; accounts receivable; building structures; machinery or equipment; land; rights under insurance policies of VALENT; and 

  

	 	(f)	***** 

 2.3 Assumption of Liabilities. After
the Closing Date, PURCHASER shall assume and be responsible for all liabilities arising out of PURCHASER’s conduct of the business relating to the Acephate Assets, and without limiting the generality of the foregoing, shall include: 

 

	 	a)	all open orders for Acephate Products listed on Schedule 2.3(a) below. 

  

	 	b)	all of VALENT’s present and future obligations as registrant with respect to maintaining the EPA Registrations and the State Registrations, 

  

	 	c)	all liabilities arising out of PURCHASER’S conduct of the business relating to Acephate Assets following the Closing Date, except as explicitly provided otherwise herein,

  

 - 6 - 

	 	d)	all liabilities arising under any Transferred Contract (i) with respect to a breach or a default thereof committed after the Closing or (ii) required by the terms of any
such contract to be performed after the Closing, 

  

	 	e)	all other liabilities expressly assumed by PURCHASER pursuant to other provisions of this Agreement. 

 2.4 Liabilities Not Assumed. PURCHASER shall not assume or have any responsibility with respect to any obligations or liability of VALENT, whether
or not relating to the Acephate Assets incurred or created prior to or on the Closing Date, including without limitation: 
  

	 	a)	liabilities arising out of conduct of the business relating to, or ownership of, Acephate Assets prior to Closing, including taxes, 

  

	 	b)	liabilities relating to Acephate Products delivered and invoiced to third parties on or before the Closing, 

  

	 	c)	all payables relating to Acephate Assets accrued on or prior to the Closing, 

  

	 	d)	all liabilities not expressly assumed by PURCHASER under this Agreement 

  

	 	e)	all liabilities arising under any transferred contract (i) with respect to a breach of default thereof committed on or prior to the Closing or (ii) required by the terms
of any such contract to be performed on or prior to the Closing, 

  

	 	f)	all liabilities resulting from, or relating to, litigation or claims arising from events on or prior to the Closing Date 

  

	 	g)	all liabilities relating to employees of VALENT or its affiliates. 

 2.5 Risk of Loss. From the date of this Agreement until the Closing Date, the risk of loss of or damage to such Acephate Assets shall be and remain that of VALENT. If, prior to the Closing Date, any significant
part of the Acephate Assets are destroyed or damaged by fire or any other casualty, PURCHASER shall have the option to cancel this Agreement by notice in writing to VALENT and not complete the transactions provided for herein, in which case all
obligations of the Parties hereunder shall forthwith terminate with no liability of either Party to the other whatsoever. 
  

 - 7 - 

 2.6 Trademarks. No transfer of any right, title or interest in or to any trademark of VALENT,
other than the Trademark Rights is contemplated by this Agreement. In particular, it is agreed that any products produced by PURCHASER by virtue of this Agreement will bear no reference to VALENT other than for purposes of the sale of the Inventory
pursuant to this Agreement. 
 2.7 Unreasonable Adverse Effects. In the event VALENT receives notice regarding unreasonable adverse
effects on the environment of or related to Acephate Technical or Acephate Products, VALENT shall immediately notify PURCHASER in accordance with the provisions of Article 13. 
 ARTICLE 3 – INVENTORY AND INVENTORY ADJUSTMENT 
 3.1 Inventory Statement. VALENT will
provide PURCHASER fifteen (15) days prior to the Closing with a written statement of its then existing Inventory by Product type and location, and the price based on VALENT’S book value thereof (“Inventory Statement”). The
Inventory Statement will be based upon a stock taking of the Inventory at all Inventory locations to be performed by VALENT through either (a) a physical inventory count or (b) obtaining written certification by warehouses in which any
such Inventory is located. 
 3.2 Physical Inventory. Within ten (10) days after receiving the Inventory Statement, PURCHASER,
shall undertake a stock taking of Inventory at all Inventory locations either through a physical inventory count or through obtaining written certification by warehouses in which any such Inventory is located. 
 3.3 Adjustments. If, following PURCHASER’s inventory as described in Section 3.2 above, PURCHASER finds that the value of the Inventory
is less or more than the Inventory Statement then the parties shall promptly meet to resolve their differences with respect thereto. 
 3.4
Post Closing Consolidation. On or after the Closing Date, if so requested by PURCHASER, VALENT shall ship the Inventory to the PURCHASER based on shipment terms FOB collect and by mutually agreed upon carriers at such locations as PURCHASER
shall designate. 
 3.5 Non-Saleable Inventory. PURCHASER shall not be required to purchase any non-saleable Inventory identified
within thirty (30) days of Closing. If, however, PURCHASER elects to accept the non-saleable Inventory the Inventory Statement shall be reduced by the value of the non-saleable inventory. 
  

 - 8 - 

 3.6 Transfer of Title and Risk of Loss. Risk of loss of, and title to, the Inventory will pass to
PURCHASER at Closing. 
 3.7 Storage. The cost of storing the Inventory will be borne by PURCHASER after the Closing Date. 

ARTICLE 4 – FACILITATION OF PURCHASER’S ABILITY TO SELL 
 4.1 VALENT will facilitate the ability of PURCHASER to sell Acephate Products on the Closing Date, including Acephate Products bearing VALENT’S name, by submitting on or before the Closing Date a Notice of
Supplemental Distribution (EPA Form 8570-5) covering all Acephate Products, identified in Schedule 4.1 below. Immediately following the Closing Date, VALENT shall submit all necessary documentation to transfer the EPA Registrations and the State
Registrations to PURCHASER. The Parties shall cooperate with each other to ensure the most rapid transfer of such Registrations. 
 ARTICLE 5 - PURCHASE
PRICE; CLOSING. 
 5.1 Purchase Price, Closing. The Purchase Price for the Acephate Assets shall be the aggregate of: 

 

	 	a)	***, plus 

  

	 	b)	The sum of the Inventory Statement, as adjusted, plus 

  

	 	c)	***. 

 5.2 Payment of Purchase Price. The Purchase
Price will be paid by wire transfer(s) in immediately available funds as follows: 
  

	 	a)	***. 

 All payments shall be made
to: 
 *** 
  

 - 9 - 

 5.3 Allocation. The Purchase Price shall be allocated as set forth on Schedule 5.3. PURCHASER and
VALENT agree to file their federal and state income tax returns (and Form 8594, if applicable) on the basis of the allocation set forth on Schedule 5.3 and neither shall thereafter take a tax return position inconsistent with such allocation unless
such inconsistent position shall arise out of or through an audit or other inquiry or examination by the Internal Revenue Service or other taxing authority. 
 5.4 Closing and Closing Date. Subject to the satisfaction or waiver of the conditions set forth herein, the consummation of the purchase and sale of the Acephate Assets (the “Closing”) shall take
place at 10:00 a.m. on Janaury 15, 2008 in the offices of VALENT, or on such other date and at such other time and place as the Parties shall agree in writing (the “Closing Date”). The PURCHASER shall commence to own and control the
Acephate Assets as of the Closing Date. 
 5.5 VALENT’s Obligations. At the Closing, VALENT shall deliver or cause to be
delivered to PURCHASER the following: 
  

	 	(a)	an executed Registration Transfer Agreement in the form attached as Schedule 5.5(a); 

  

	 	(b)	an executed Bill of Sale for all of the Acephate Assets substantially in the form attached hereto as Schedule 5.5(b); 

  

	 	(c)	an Assignment of Trademark and Assignment of Patents, substantially in the forms attached hereto as Schedule 5.5(c); 

  

	 	(d)	all VALENT Technical and Market Information in hard copy and, where possible, on computer diskettes or other computer-readable media; 

  

	 	(e)	all necessary paperwork required to discontinue or assign to PURCHASER, as the Parties may agree, its State Registrations as identified on Schedule 5.5(e); and

  

	 	(f)	an Assignment and Assumption Agreement in the form attached as Schedule 5.5(f). 

  

 - 10 - 

 ARTICLE 6 - ORTHENE TRADEMARK. 
 In a Trademark License Agreement dated September 16, 1991, (“Trademark License”) Chevron Chemical Company granted VALENT an exclusive, fully paid and irrevocable license to use the trademark
“Orthene” in the United States on Acephate Products sold by VALENT for commercial uses. The Scotts Company and its affiliate OMS Investments, Inc., is the successor-in-interest to Chevron Chemical Company as Licensor under the Trademark
License and is the current owner of the Orthene Trademark. VALENT does not have right to grant sublicenses under the Trademark Agreement, however, VALENT will use commercially reasonable efforts to facilitate a grant of license from OMS,
Investments, Inc. to PURCHASER to use the Orthene Trademark in the United States for use on Acephate Products sold for commercial uses 
 ARTICLE 7 –
REPRESENTATIONS AND WARRANTIES OF VALENT. 
 VALENT hereby represents and warrants to PURCHASER, as of the date hereof and as of the
Closing Date, as follows: 
 7.1 Organization and Authorization. VALENT is a corporation duly organized, validly existing and in good
standing under the laws of the State of California and has all requisite corporate power and authority and has been duly authorized by all requisite corporate action to enter into this Agreement and to carry out the transactions contemplated herein.
This Agreement has been duly and validly executed and delivered by VALENT and constitutes VALENT’s legal, valid and binding obligation, enforceable in accordance with its terms, except as limited by (a) applicable bankruptcy, insolvency,
reorganization, moratorium or other laws of general application affecting the enforcement of creditors’ rights generally, and (b) general principles of equity that restrict the availability of equitable remedies. 
 7.2 Title. VALENT has good, valid and marketable title to the Acephate Assets and has complete and unrestricted power and the unqualified right to
sell, convey, assign and transfer and deliver the Acephate Assets to PURCHASER as provided herein and, as of the Closing Date, has signed no contracts with any third party to convey title, licenses, or any other rights to the Acephate Assets. The
assignments and other instruments to be executed and delivered by VALENT to PURCHASER pursuant to this Agreement will, when duly executed and delivered, effectively vest in PURCHASER good, valid and marketable title to the Acephate Assets, free and
clear of any lien or encumbrance. Furthermore, VALENT represents and warrants that VALENT is not aware of any litigation, present or threatened, or any claim adverse to VALENT’s exclusive ownership of such Acephate Assets. 
  

 - 11 - 

 7.3 Consents and Approvals. Except as set forth on Schedule 7.1.3, the execution, delivery and
performance by VALENT of this Agreement and the consummation of the transactions contemplated hereby require no action by or in respect of, or filing with, or consent, approval, authorization from, any person or Governmental Authority. Neither the
execution, delivery and performance by VALENT of this Agreement nor the consummation of the transactions contemplated hereby (with or without the giving of notice or the lapse of time, or both) (a) will violate any provision of the Articles of
Incorporation or Bylaws of VALENT, (b) will violate any provision of any law, statute, rule or regulation to which VALENT is subject, (c) will violate any judgment, order, writ or decree of any court or Governmental Authority applicable to
VALENT, or (d) will violate, result in a breach of or result in a default (or give rise to any right of termination, cancellation or acceleration) under any of the terms, conditions or provisions of any note, bond, mortgage, indenture, license,
franchise, permit, lease, agreement or other instrument or obligation to which VALENT is a party, or by which VALENT or any of its respective properties or assets are bound; excluding from clauses (b), (c) and (d) requirements, violations,
breaches or defaults that (i) individually or in the aggregate, would not have a Material Adverse Effect on VALENT, or (ii) are applicable solely as a result of any acts or omissions by, or any facts pertaining to, PURCHASER. 

7.4 Additional Documents. VALENT will execute such further documents and cooperate with PURCHASER in such manner as shall be or become
reasonably necessary to effectuate the transfer and delivery of the Acephate Assets provided for herein and otherwise to carry out the intent of this Agreement. 
 7.5 Disclaimer. VALENT makes no guarantee or representation and expressly denies any guarantee or representation of success of any business which PURCHASER may choose to enter into utilizing the said Acephate
Assets. 
 7.6 Claims. VALENT has not been contacted by, nor is VALENT aware of, any party who has made, has threatened to make or
could make a claim that the use of the VALENT Technical and Market Information and/or the formulation, sale or use of the Acephate Products pursuant to the EPA Registrations will infringe on any U.S. or foreign patent rights. VALENT 

  

 - 12 - 

 
represents and warrants that VALENT has not been contacted by, nor is VALENT aware of, any party who has made, has threatened to make or could make a claim
that the use of the VALENT Trademark Rights will infringe on any U.S. or foreign trademark rights. VALENT represents and warrants that VALENT has not been contacted by, nor is VALENT aware of, any party who has made, has threatened to make or could
make a claim that the use of the Patents set forth in Schedule 1.23 will infringe on any U.S. or foreign patent rights. VALENT represents and warrants that VALENT has not been contacted by, nor is VALENT aware of, any party who has made, has
threatened to make a claim or threatened litigation involving VALENT’S Proprietary Information, non-proprietary information, or Non-FIFRA information, or any other claim involving the Acephate Assets. 
 7.7 Specifications. VALENT represents and warrants that the Acephate Technical and the Acephate Products produced and packaged will meet the
specifications set forth on Schedule 7.7. 
 7.8 Compliance with Law. VALENT is in compliance in all material respects with all
statutes, laws, ordinances, regulations, rules and orders of all Governmental Authorities applicable to its business or operations. 
 7.9
Storage. VALENT is in material compliance with all terms and conditions of its contracts for the warehousing of all Inventory. There are no notices, orders, suits, judgments, or other proceedings relating to material breaches of any such
contracts that have not been corrected. 
 7.10 Brokers, Finders and Investment Bankers. VALENT has not employed any broker, finder,
investment banker, or other intermediary or incurred any liability for any investment banking fees, financial advisory fees, brokerage fees, finders’ fees, or other similar fees in connection with the transactions contemplated by this
Agreement. 
 7.11 Inventory. VALENT represents and warrants that the Inventory is good and saleable and has been maintained in the
ordinary course of business. 
 7.12 Registrations. VALENT represents and warrants that (a) the EPA and State Registrations as
listed on Schedule 1.14 and Schedule 1.25 respectively are validly existing and (b) there are no circumstances justifying invalidation or restriction of registration rights or registration data packages. 
  

 - 13 - 

 7.13 Transferred Contracts. Except as set forth on Schedule 7.13, VALENT has no knowledge of
breach or default of Transferred Contracts and that each Transferred Contract is legal, valid and binding and in full force and effect and will continue to be so upon consummation of this transaction. 
 7.14 Litigation. There is no suit, claim, action, proceeding or investigation pending or, to the knowledge of VALENT, threatened against VALENT
that could reasonably be expected to adversely affect VALENT’s performance under this Agreement or prevent or materially delay the Closing. VALENT is not subject to any outstanding order, writ, injunction or decree that could materially and
adversely affect VALENT’s performance under this Agreement. 
 7.15 Financial Information. Financial Information presented to
PURCHASER for the years 2003 – 2007 appearing on Schedule 7.15 are complete, accurate and were recorded in the ordinary course according to standard accounting practices of VALENT 
 ARTICLE 8 – REPRESENTATIONS AND WARRANTIES OF PURCHASER. 
 PURCHASER represents and warrants to
VALENT as follows: 
 8.1 Organization and Authorization. PURCHASER is a corporation duly organized, validly existing and in good
standing under the laws of the State of California and has the necessary corporate power and has been duly authorized by all requisite corporate action to enter into and consummate the transactions described herein. 
 8.2 No Guarantee. PURCHASER acknowledges that by its purchase of the Acephate Assets, it is not acquiring any guarantee or representation of
success of any business which PURCHASER chooses to operate utilizing said Acephate Assets. 
 8.3 Consents and Approvals. The
execution, delivery and performance by PURCHASER of this Agreement and the consummation of the transactions contemplated hereby require no action by or in respect of, or filing with, or consent, approval, authorization from, any person or
Governmental Authority that if not obtained or made will (i) individually or in the aggregate have a Material Adverse Effect on VALENT, or (ii) prevent, delay, obstruct, hinder or otherwise affect the Closing. Neither the execution,
delivery and performance by PURCHASER 

  

 - 14 - 

 
of this Agreement nor the consummation of the transactions contemplated hereby (with or without the giving of notice or the lapse of time, or both)
(a) will violate any provision of the Articles of Incorporation or Bylaws of PURCHASER, (b) will violate any provision of any law, statute, rule or regulation to which PURCHASER is subject, (c) will violate any judgment, order, writ
or decree of any court or Governmental Authority applicable to PURCHASER, or (d) will violate, result in a breach of or result in a default (or give rise to any right of termination, cancellation or acceleration) under any of the terms,
conditions or provisions of any note, bond, mortgage, indenture, license, franchise, permit, lease, agreement or other instrument or obligation to which PURCHASER is a party, or by which any of them or any of their respective properties or assets
are bound; excluding from clauses (b), (c) and (d) requirements, violations, breaches or defaults that (i) individually or in the aggregate, would not have a PURCHASER Material Adverse Effect, or (ii) are applicable solely as a
result of any acts or omissions by, or any facts pertaining to, VALENT. 
 8.4 Financing. PURCHASER will have at the Closing
sufficient immediately available funds in cash to enable PURCHASER to pay the Purchase Price and to effect the consummation of the Acquisition. 
 8.5 Size of Acquiring Person. For purposes of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), PURCHASER, as an “acquiring person” (as defined under 16 C.F.R. Parts 801-803), does not
have sufficient annual net sales or total assets to meet the “size of the persons” test nor does the size of the transaction require a pre-merger notification report form filing under HSR. 
 8.6 VALENT’s Inducement. In entering into this Agreement, PURCHASER represents and warrants that, except as set forth in Article 10.5.1, it
has not been induced nor has PURCHASER relied upon any representations, warranties or statements of VALENT or any of the respective officers, directors or representatives of VALENT other than representations, warranties or statements set forth in
this Agreement, whether or not such representations, warranties or statements have actually been made in writing or orally, relating to (a) the earnings, assets, net worth, properties, prospects, business, profits or condition of VALENT,
(b) the status of the relationships of VALENT with its respective customers and suppliers or (c) any other matter. VALENT shall not have or be subject to any liability of the PURCHASER or any other 

  

 - 15 - 

 
person resulting from the distribution to PURCHASER, or PURCHASER’s use or reliance on, any such information or any information, documents, or material
made available to PURCHASER in any data rooms, virtual data rooms, management presentations or in any other form in expectation of, or in connection with, the transactions contemplated hereby, except to the extent that VALENT makes a representation
or warranty in this Agreement with respect to such information, documents or materials. 
 8.7 Litigation. There is no suit, claim,
action, proceeding or investigation pending or, to the knowledge of PURCHASER, threatened against PURCHASER that could reasonably be expected to adversely affect PURCHASER’s performance under this Agreement or prevent or materially delay the
Closing. PURCHASER is not subject to any outstanding order, writ, injunction or decree that could materially and adversely affect PURCHASER’s performance under this Agreement. 
 8.8 Brokers, Finders and Investment Bankers. PURCHASER has not employed any broker, finder, investment banker, or other intermediary or incurred
any liability for any investment banking fees, financial advisory fees, brokerage fees, finders’ fees, or other similar fees in connection with the transactions contemplated by this Agreement. 
 ARTICLE 9 – INDEMNIFICATION. 
 9.1
VALENTs’ Agreement to Indemnify. Subject to the terms and conditions set forth herein, from and after the Closing, VALENT shall indemnify and hold harmless PURCHASER, its Affiliates, any of their respective successors or assigns and
their respective partners, members, directors, officers, employees and other agents and representatives (each, a “PURCHASER Indemnified Party”) from and against any and all liabilities, judgments, claims, suits, proceedings, settlements,
assessments, losses, damages, Taxes, liens, penalties, charges, fees, costs and expenses (including, without limitation, interest obligations, costs of investigation and defense, court costs and reasonable attorney and other reasonable professional
advisor and reasonable consulting fees and reasonable expenses) but specifically excluding consequential damages, punitive damages and exemplary damages (collectively, “PURCHASER Damages”) incurred or suffered by a PURCHASER Indemnified
Party as a result of or arising out of or in connection with (i) any misrepresentation or breach of any representation or warranty contained in Article 9 of this Agreement or (ii) the nonfulfillment by VALENT of any covenant or 

  

 - 16 - 

 
agreement made by it in this Agreement, or (iii) for Liabilities not assumed. Notwithstanding the foregoing, in no event shall PURCHASER Damages
include, nor shall the PURCHASER Indemnified Parties make any claim for indemnification with respect to, any liability, assessments, losses, charges, costs and expenses (including, without limitation, interest, court costs, reasonable
attorneys’ fees and expenses) to the extent arising from any liability reflected as a liability of the PURCHASER in the Agreement. 
 9.2 PURCHASER’s Agreement to Indemnify. Subject to the terms and conditions set forth herein, from and after the Closing, PURCHASER shall indemnify and hold harmless VALENT and its respective Affiliates, any of their respective
successors or assigns and their respective partners, members, directors, officers, employees and other agents and representatives (each, a “VALENT Indemnified Party”) from and against any and all liabilities, judgments, claims, suits,
proceedings, settlements, assessments, losses, damages, Taxes, liens, penalties, charges, fees, costs and expenses (including, without limitation, interest obligations, costs of investigation and defense, court costs and reasonable attorney and
other reasonable professional advisor and reasonable consulting fees and reasonable expenses) but specifically excluding consequential damages, punitive damages and exemplary damages (collectively, “VALENT Damages”) incurred by a VALENT
Indemnified Party as a result of or arising out of (i) any misrepresentation or breach of any representation or warranty contained in Article 8 of this Agreement, or (ii) the nonfulfillment by PURCHASER of any covenant or agreement made by
it in this Agreement, or (iii) the Assumed Liabilities. (The PURCHASER Indemnified Parties and VALENT Indemnified Parties referred to in 9.1 and 9.2 are sometimes referred to collectively herein as the “Indemnified Parties”;
“PURCHASER Damages” and “VALENT Damages” are sometimes referred to collectively herein as “Damages”). 
 9.3
Third Party Indemnification. The obligations of VALENT and PURCHASER (as applicable, the “Indemnifying Party”) to indemnify Indemnified Parties under Section 9.1 or Section 9.2 hereof, respectively, with respect to Damages
resulting from the assertion of liability by third parties (each, as the case may be, a “Claim”), shall be subject to the following terms and conditions: 
  

	 	(a)	 Promptly after receipt by an Indemnified Party of notice by a third party of any complaint or the commencement of any action or proceeding 

  

 - 17 - 

	 	 
with respect to which such Indemnified Party may be entitled to receive payment from the other party for Damages (a “Claims Event”), such
Indemnified Party shall, within thirty (30) days, notify VALENT or PURCHASER, as the appropriate Indemnifying Party, of such complaint or of the commencement of such action or proceeding; provided, however, that the failure to so
notify the Indemnifying Party shall not relieve the Indemnifying Party from liability under this Agreement with respect to such claim, except to the extent that, such failure to notify the Indemnifying Party shall have adversely prejudiced the
Indemnifying Party. In addition, the Indemnified Party shall provide to the Indemnifying Party as promptly as practicable thereafter such information and documentation as may be reasonably requested by the Indemnifying Party to support and verify
the claim asserted, so long as such disclosure would not violate the attorney-client privilege of the Indemnified Party. The Indemnifying Party may, at its option, undertake the defense thereof by representatives of its own choosing;
provided, that any Indemnified Party may, in any event, at its own expense, monitor and participate in, but not control, the defense of such claim. If the Indemnifying Party within thirty (30) days after notice of any such Claim fails to
assume the defense of such Claim, the Indemnified Party will (upon further notice to the Indemnifying Party) have the right to undertake the defense, compromise or settlement of such claim on behalf of and for the account and risk, and at the
expense, of the Indemnifying Party; provided, however, that as long as the Indemnifying Party is reasonably contesting any claim in good faith, the Indemnified Parties shall not pay or settle any such claim. If the Indemnifying Party
chooses to defend or prosecute a Claim, the Parties hereto shall cooperate with respect to the defense or prosecution of such Claim. Such cooperation shall include providing to the Indemnifying Party, after reasonable notice of the need therefor,
records and information that are reasonably relevant to such Claim, and making employees available on a mutually convenient basis to provide additional information and explanation of any materials provided hereunder. 

  

 - 18 - 

	 	(b)	Anything in this Section 9.3 to the contrary notwithstanding, the Indemnifying Party shall not enter into any settlement or compromise of any action, suit or proceeding or
consent to the entry of any judgment (i) which does not include as an unconditional term hereof the delivery by the claimant or plaintiff to the Indemnified Parties of a written release from all liability in respect of such action, suit or
proceeding or (ii) for other than monetary damages without the prior written consent of the Indemnified Party, which consent shall not be unreasonably withheld or delayed. 

 9.4 Survival; Time to Assert Claims. 
  

	 	(a)	Survival. The representations warranties, covenants and agreements contained herein, except for covenants and agreements to be performed by the Parties prior to the Closing,
will not be extinguished by the Closing but will survive subject to the limitations set forth in subsection (b) below 

  

	 	(b)	Representations and warranties of the parties shall survive for eighteen (18) months following the Closing. The indemnification obligations of the parties set forth in
Sections 9.1(i) and 9.2 (i) shall survive for a period of eighteen (18) months following the Closing. The indemnification obligations of the parties set forth in Sections 9.1(ii), and 9.2(ii) shall survive the Closing without limitation.
And the indemnification obligations of the parties set forth in Sections 9.1(iii) and 9.2(iii) shall survive the Closing until the expiration of the applicable statute of limitations with respect to the indemnification claim being asserted.

  

 - 19 - 

 ARTICLE 10 – COVENANTS. 
 10.1 Conduct of Business of VALENT. Except as contemplated by this Agreement or as consented to by PURCHASER, during the period commencing on January 1, 2007 to the Closing Date (a) VALENT has
conducted, and shall conduct its business in the ordinary course consistent with past practices and has used and will use its commercially reasonable efforts to preserve and keep intact the business of selling Acephate Products, and preserve its
relationships with customers, suppliers and others having business dealings, with VALENT; and (b) VALENT shall not take any action that would reasonably be expected (i) to have a Material Adverse Effect and (ii) to cause any of the
representations and warranties of VALENT contained herein not to be true and correct in any material respect at any time between the date hereof and the Closing Date. 
 10.2 Additional Agreements. Subject to the terms and conditions herein provided, each of the Parties hereto agrees to, both prior to and after the Closing, use all commercially reasonable efforts to take, or
cause to be taken, all actions and to do, or cause to be done, all things necessary, proper or advisable to consummate and make effective as promptly as practicable the transactions contemplated by this Agreement and to cooperate with each other and
to keep each other informed in connection with the foregoing, including using all commercially reasonable efforts (a) to obtain all necessary waivers, consents and approvals from other parties, (b) to obtain all necessary consents,
approvals and authorizations as are required to be obtained under any federal, state or foreign law or regulations, (c) to lift or rescind any injunction or restraining order or other order adversely affecting the ability of the Parties to
consummate the transactions contemplated hereby, (d) to effect all necessary Registrations, and (e) to fulfill all conditions to this Agreement. VALENT shall, at any time from and after the Closing, upon the request of PURCHASER and at
PURCHASER’s expense, do, execute, acknowledge and deliver, and cause to be done, executed, acknowledged and delivered, all such further acts, assignments, transfers, conveyances, powers of attorney or assurances as may be reasonably required to
transfer, convey, grant and confirm to and vest in PURCHASER good title to all of the Acephate Assets, free and clear of all liens. 
 10.3
Access to Information. 
 10.3.1 From the Effective Date to the Closing, VALENT shall afford to PURCHASER and
PURCHASER’s employees, agents and representatives (collectively, “Representatives”) reasonable access to its properties, accounts, contracts, books and records and to furnish PURCHASER and Representatives such existing
financial, operating and other data 

  

 - 20 - 

 
and information as it may reasonably request; provided, however, that any such investigation by PURCHASER and Representatives shall be
conducted pursuant to reasonable prior notice during normal business hours under the supervision of VALENT’s personnel and in such a manner as to maintain the confidentiality of the transactions contemplated by this Agreement and shall not
interfere with the business operations of VALENT. 
 10.3.2 PURCHASER shall afford VALENT with such information concerning
PURCHASER as may be necessary in connection with the transactions contemplated hereby and to verify the performance of and compliance with their representations, warranties, covenants and conditions herein contained. 
 10.3.3 The Confidentiality Agreement by and between VALENT and PURCHASER dated as of July 27, 2007 (the “Confidentiality
Agreement”) shall remain in full force and effect and shall survive the execution and delivery of this Agreement and the termination of this Agreement for any reason whatsoever. 
 10.4 Public and Employee Announcements. PURCHASER and VALENT, and their respective affiliates, shall not issue any press release or make any
public statement with respect to the purchase and sale of the Acephate Assets or the terms thereof without the prior consent of the other Party, except as may be required by law, court process or by obligations pursuant to any securities exchange.
PURCHASER and VALENT agree to reasonably cooperate regarding any written communications made to the employees of VALENT during the period from the Effective Date to the Closing Date which relate to the sale of the Acephate Assets, and shall confer
prior to the dissemination of any such written communications. 
 10.5 Restrictive Covenants. 
 10.5.1 Conditioned and effective only upon the occurrence of the Closing, as a material inducement to cause PURCHASER to enter into this
Agreement, VALENT agrees that for a period of ten (10) years from and after the Closing Date, not to sell or engage in the resale of Acephate Products or Active Ingredient in the United States. 
 10.6 Limited Right to Use Valent Name. VALENT covenants and agrees that PURCHASER may use the VALENT name, trademarks, and logos in connection
with the sale of Inventory and Products until such time as applicable registrations have been transferred to PURCHASER. 
  

 - 21 - 

 10.7 Reliance on Registrations. VALENT covenants that PURCHASER may sell Acephate Products in
reliance on VALENT’S EPA and State Registrations until such time as the Registrations have been transferred to PURCHASER. 
 10.8
PURCHASER Covenants. PURCHASER covenants and agrees to use its commercially reasonable efforts to obtain any and all consents for the transfer of contracts, agreements, permits, licenses (as provided hereunder) not obtained by the Closing
Date 
 10.9 **** If the parties agree to such valuation, then PURCHASER shall promptly pay VALENT one half of such valuation in cash. If the
parties are unable to agree to such value within thirty (30) days, then the parties shall submit the matter to a public accounting firm of their mutual choice. The parties agree to cooperate with the accounting firm and to provide access to
people, data and documents relevant to the dispute promptly upon request. The accounting firm will endeavor to reach a decision within thirty (30) days of commencing its review; such decision will binding upon the parties. For purposes of this
paragraph “Disputed Amount” shall mean the amount by which VALENT’s valuation exceeds PURCHASER’s valuation. To the extent that the accounting firm’s valuation includes (x) greater than or equal to fifty percent
(50%) of the Disputed Amount, then PURCHASER shall pay all of the accounting firm’s fees and expenses for this exercise; (y) greater than or equal to twenty five (25%) but less than fifty percent (50%) of the Disputed
Amount, then the parties shall evenly split the accounting firm’s fees and expenses for this exercise; and (z) less than twenty five percent (25%) of the Disputed Amount, then VALENT shall pay all of the accounting firm’s fees
and expenses for this exercise. Following the accounting firm’s decision, PURCHASER agrees to pay VALENT promptly one half of the accounting firm’s valuation. 
 10.10 ***. If payment is tendered to PURCHASER, PURCHASER shall facilitate the transfer of the payment to VALENT within thirty (30) days. 
  

 - 22 - 

 ARTICLE 11 – CONDITIONS TO OBLIGATIONS OF VALENT AND PURCHASER 
 The obligations of the Parties hereunder shall be subject to the fulfillment at or prior to the Closing Date of each of the following conditions:

 11.1 Representations and Warranties True at Closing Date. The representations and warranties made by either Party herein shall be
true and correct in all material respects on and as of the Closing Date with the same force and effect as though such representations and warranties had been made on and as of such date. 
 11.2 Use of Assets. All of the Acephate Assets shall be used, operated, maintained and repaired in a normal business manner by VALENT at all times
up through and including the Closing Date, and VALENT shall not subject or allow any of the Acephate Assets to become subject to any lien or encumbrance of any nature after the date hereof. 
 11.3 Litigation. No suit, investigation, action or other proceeding shall be pending or overtly threatened against VALENT or PURCHASER before any
court or governmental agency, which has resulted in the restraint or prohibition of any such party from entering into this Agreement or consummating the transactions contemplated hereby, or, could in the reasonable opinion of counsel for VALENT,
result in the obtaining of material damages or other relief from any such Party, as a result of entering into this Agreement or consummating the transactions contemplated hereby. 
 11.4 Required Governmental Approvals. All governmental authorizations, consents and approvals necessary for the valid consummation of the
transactions contemplated hereby shall have been obtained and shall be in full force and effect. 
 11.5 No Material Adverse Effect.
With respect to the Acephate Assets, VALENT shall not have suffered any Material Adverse Effect since January 1, 2007 (whether or not such change is referred to or described in any Schedule) in its business, prospects, financial condition,
working capital (excluding customary seasonal changes), assets, liabilities (absolute, accrued, contingent or otherwise), reserves or operations. No suit, investigation or claim against VALENT has or, with the passage of time, will have a Material
Adverse effect upon the Acephate Assets. 
 11.6 Approval of Sumitomo Chemical Company, Inc. The Board of Directors of VALENT’s
parent Company, Sumitomo Chemical Company, Inc. shall have authorized the transaction contemplated by this Agreement. 
  

 - 23 - 

 11.7 Assignment/Grant of Trademark Rights. VALENT shall have obtained either (a) an assignment of
VALENT’s Trademark Rights to PURCHASER or (b) a new License Agreement giving PURCHASER the right to use the name ORTHENE in the United States. 
 ARTICLE 12 – VALENT POST-CLOSING OBLIGATIONS. 
 12.1 VALENT Obligations. VALENT shall perform the following
post-Closing obligations: 
  

	 	(a)	Send Ag Data, Charlotte, North Carolina, a “letter of authorization” to provide PURCHASER with EDI transactions for Acephate Products and provide a copy to PURCHASER in a
timely manner; 

  

	 	(b)	Maintain all EPA Registrations and State Registrations until such time as the Registrations have been transferred to PURCHASER; 

  

	 	(c)	Notify warehouses as identified on Schedule 12.1(c) of the Inventory transfer to PURCHASER and provide a copy to PURCHASER in a timely manner; 

  

	 	(d)	Notify the lab(s) as identified on Schedule 12.1(d) of transfer of ownership of the Studies (wet tissue) and provide a copy to PURCHASER in a timely manner; and

  

	 	(e)	Deliver the Studies via an archive transfer within sixty (60) days of the Closing to a location chosen by PURCHASER. 

 ARTICLE 13 – NOTICES. 
 13.1 Notice to Party
or Parties. All notices in connection with this Agreement shall be given by notice in writing, hand delivered or sent by courier service with a copy sent by facsimile transmission (transmission confirmed). All such notices shall be sent to the
telecopier number and addresses specified hereafter, or to such other number or address the Parties may have last specified by notice to the other Party sent as aforesaid. All such notices shall be effective upon receipt of the written notice.

  

 - 24 - 

 13.2 Addresses of Notice. For the purpose of sending notices and other communications relative to
this Agreement, the addresses of the Parties are as follows: 
  

			
	 For VALENT:
	  	 Valent U.S.A. Corporation
 Anita Dale
 Senior Director, Business Development
 1600 Riviera Avenue, Suite
200
 Walnut Creek, CA 94596
 Phone:
(925) 256-2839
 Facsimile No.: (925) 817-5004

		
	 With Copy to:
	  	 Valent U.S.A. Corporation
 Robin M. Demouth, Vice
President & General Counsel
 1600 Riviera Avenue, Suite 200
 Walnut Creek, CA 94596
 Phone: (925) 256-2758

		
	 For PURCHASER:
	  	 AMVAC Chemical Corporation
 Glen Johnson
 Senior Vice President, Business Development
 4695 MacArthur Court, Suite 1250

 Newport Beach, CA 92660
 Phone:
(949)260-1200

 ARTICLE 14 - TERMINATION; AMENDMENT; WAIVER. 
 14.1 Termination. This Agreement may be terminated at any time prior to the Closing: 
  

	 	(a)	By mutual written consent of PURCHASER and VALENT; 

  

	 	(b)	By VALENT, without liability, if PURCHASER breaches any of its representations and warranties contained in this Agreement or fails to perform any of its covenants or agreements
contained in this Agreement, and such breach or failure to perform cannot be or has not been cured prior to the date that is fifteen (15) days from the date upon which PURCHASER is notified of such breach or failure to perform;

  

	 	(c)	By PURCHASER, without liability, if VALENT breaches any of its representations and warranties contained in this Agreement or fail to perform any of their respective covenants or
agreements contained in this Agreement, and such breach or failure to perform cannot be or has not been cured prior the date that is fifteen (15) days from the date upon which VALENT is notified of such breach or failure to perform; or

  

 - 25 - 

	 	(d)	By either the VALENT or PURCHASER, without liability, if the Closing shall not have occurred on or before February 15, 2008. 

  

	 	(e)	By VALENT, without liability, if it fails to receive approval of the Board of Directors of its parent company, Sumitomo Chemical Company, Inc. with respect to the transaction
contemplated by this Agreement. 

  

	 	(f)	By PURCHASER, without liability, if a) VALENT fails to obtain an assignment of VALENT’s Trademark Rights to PURCHASER, or b) fails to obtain for PURCHASER a new License
Agreement giving PURCHASER the right to use the name ORTHENE in the United States. 

  

	 	(g)	By PURCHASER if there is a Material Adverse Effect between the date of the execution hereof and the Closing. 

 14.2 Effect of Termination. In the event of the termination of this Agreement as provided in Section 14.1 hereof, this Agreement shall
forthwith become void, and all obligations of PURCHASER and VALENT shall terminate, except as set forth in this Section 14 and in Section 10.3.3 hereof; provided that the foregoing shall not relieve any defaulting or breaching party for
liability for damages actually incurred as a result of any breach of this Agreement. 
 ARTICLE 15 – GENERAL 
 15.1 Governing Law. This Agreement shall be construed in accordance with and governed by the laws of the State of California, without regard to
such states choice of law principles or rules. Any action to enforce the terms of this Agreement, or arising out of the subject matter of this Agreement, shall be brought in the State of California. 
 15.2 Arbitration. Any matter that arises involving the performance or interpretaton of this Agreement that the Parties are unable to settle by
mutual agreement, and in any case in which this Agreement provides for the adjustments or determinations by mutual agreement of the Parties and the Parties are unable to reach a mutually satisfactory agreement within a reasonable time, shall be
settled and determined by an Arbitrator to be chosen by mutual agreement between the Parties. The arbitration proceeding shall be conducted in accordance with the prevailing rules and regulations of the American Arbitration Association. 

 

 - 26 - 

 15.3 Entire Agreement. This Agreement (including the Schedules attached hereto) contains the
entire agreement between VALENT and PURCHASER and supersedes and merges all pre-existing agreements between VALENT and PURCHASER representing its subject matter (with the express exception of the Confidentiality Agreement dated July 27, 2007
which is hereby confirmed by the Parties in all respects and incorporated by reference to the same degree as if expressly set forth herein). Any prior representations, warranties, promises or conditions whether the same be oral or written, express
or implied, in connection with the subject matter which are not incorporated by the terms of this Agreement shall not be binding upon either Party, and this Agreement is executed and delivered on the basis of this understanding. 
 15.4 Amendment. Neither Party shall be bound by amendment, modification or rescission of any provisions hereof unless such amendment, modification
or rescission is in writing, signed by the other Party, and specifically refers to the provisions of this Agreement which it purports to amend, modify or rescind. 
 15.5 Waiver. No waiver of any breach of any term or condition of this Agreement shall be deemed a waiver of any other terms or conditions herein or of a repeated similar breach. 
 15.6 Assignment. This Agreement shall not be assigned without the prior written consent of the other Party; provided that either Party may
unilaterally assign all or any of its rights under this Agreement to any affiliate or subsidiary without prior consent. 
 15.7
Validity. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provisions of this Agreement, all of which shall remain in full force and effect. 
 15.8 Gender and Number. Where the context requires, the use of a pronoun of one gender or the neuter is to be deemed to include a pronoun of the
appropriate gender, singular words are to be deemed to include the plural, and vice versa. 
 15.9 Descriptive Headings. The
descriptive headings herein are inserted for convenience of reference only and are not intended to be part of or to affect the meaning or interpretation of this Agreement. 
  

 - 27 - 

 15.10 Counterparts. This Agreement may be executed in two or more counterparts, each of which
shall be deemed to be an original, but all of which shall constitute one and the same agreement. 
 [Signature page on next page]

  

 - 28 - 

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be duly executed as of the
Effective Date first set forth above. 
  

									
	PURCHASER	 		 	VALENT U.S.A. CORPORATION
					
	By:	 	 	 		 	By:	 	 
	Name:	 	Eric G. Wintemute	 		 	Name:	 	Trevor Thorley
	Title:	 	President & CEO	 		 	Title:	 	President & COO
					
	Date:	 		 		 	Date:	 	
					
	By:	 	 	 		 	By:	 	 
	Name:	 	Timothy J. Donnelly	 		 	Name:	 	Robin M. Demouth
	Title:	 	Vice President & General Counsel	 		 	Title:	 	Vice President, General Counsel, Secretary and Treasurer
					
	Date:	 		 		 	Date:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}]]